WASHINGTON, Dec. 29 /PRNewswire/ -- Food & Friends, an organization that delivers critical nutritious meals to people living with HIV/AIDS and other life-threatening illnesses throughout the Washington Metropolitan area, is planning ahead to have enough volunteers during upcoming winter storms. Food & Friends m
PITTSBURGH, Dec. 21 /PRNewswire/ -- Demegen, Inc. (OTC Bulletin Board: DBOT - news) reports confirmation that Demegen s antimicrobial peptide vaginal microbicide is effective in killing Chlamydia, a sexually transmitted organism that infects over 4 million people annually in the USA. These new research results are impo
TORONTO, Dec. 20 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGIN - news) reported today that it has been granted French regulatory approval for its TRUGENE(TM) HIV-1 Genotyping Kit by the Agence Francaise De Securite Sanitaire Des Produits de Sante (AFSSAPS). Visible Genetics TRUGENE HIV-1 Genotyping Kit is t
SEATTLE, Dec. 19 /PRNewswire/ -- The Chicken Soup Brigade, which provides support services to people with HIV and AIDS, today will receive the gift of $4,000 worth of gently used home furnishings for its Thrift Store through an annual holiday donation program, Sharing With Our Communities, coordinated by ExecuStay by M
SOUTH PLAINFIELD, N.J., Dec. 19 /PRNewswire/ -- PTC Therapeutics today announced the Company has been awarded a Phase I Small Business Innovation Research (SBIR) Grant from the National Institutes of Health. Funding from this grant will be used to advance PTC s RNA-based approach for developing novel HIV drugs that tar
SAN JUAN, Puerto Rico , Dec. 18 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced presentations of HE2000 clinical data at the Frontiers in Drug Development for Antiretroviral Therapies (HIV DART) meeting being held in San Juan, Puerto Rico December 17-21. HE2000 is the subject of an ora
SAN JUAN, Puerto Rico , Dec. 18 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH - news) today announced presentations of HE2000 clinical data at the Frontiers in Drug Development for Antiretroviral Therapies (HIV DART) meeting being held in San Juan, Puerto Rico December 17-21. HE2000 is the subject of
WASHINGTON, Dec. 13 /PRNewswire/ -- Commemorating World AIDS Day 2000, Friday, December 1, 2000, the BeHealthyLifestyles Group, Inc. in conjunction with the AmASSI Center of Los Angeles, CA, and the ARK Foundation of Africa, conducted a first of a kind, live, global webcast event with teens discussing HIV/AIDS, from th
SAN DIEGO, Dec. 13 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL - news) announced that an investigative HIV vaccine program was highlighted Tuesday as a key research initiative for Merck & Co. , Inc. (NYSE: MRK - news) at Merck s annual business briefing. After noting the many failures to date and the challenge
TETERBORO, N.J., Dec. 12 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX - news), the nation s leading provider of gene-based medical testing, information and services, announced that its researchers, in collaboration with the Center for AIDS Research at Stanford University School of Medicine, have identified
BURLINGTON, N.C., Dec. 12 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH - news; LabCorp(R)) today announced the introduction HIV GenoSure(TM), a new HIV genotypic resistance assay, to its portfolio of HIV resistance testing services. This latest offering from LabCorp, called HIV GenoSure(TM),
TORONTO, Dec. 11 /PRNewswire/ - William Multi-Tech Inc., ( Multi-Tech ) (TSE:WIM) announced today that C Sixty Inc. ( C Sixty ) a privately held biotechnology company, in which Multi-Tech has a 40% ownership interest, has begun upscale manufacturing of its lead fullerene based drug candidate for treatment of patients w
ST. LUCIA, West Indies, Dec. 11 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported new findings on the Company s anti-HIV agents PRO 542 and PRO 140. The results were described Saturday at the Collaborative Research Seminar on HIV Entry and Fusion Inhibitors, a gathering of the world s leading expe
LOS ANGELES, Dec. 8 /PRNewswire/ -- Donald B. Kohn, M.D., and Joseph A. Church, M.D., have begun a Phase 1 clinical trial to determine if gene therapy is effective in treating children infected with HIV-1. Artificial genes have been developed which block HIV-1, the AIDS virus, from growing in human cells, said Kohn, di
CLEVELAND, Dec. 8 /PRNewswire/ -- Empyrean Bioscience, Inc. (OTC Bulletin Board: EMDG) announced that the first in a series of Phase III clinical trials has begun in Brazil to determine the effectiveness of the GEDA Plus(R) microbicidal contraceptive gel in preventing the spread of HIV, other sexually transmitted disea
TORONTO, Ontario, Dec. 5 /PRNewswire/ -- Medical Resorts International, Inc. (Pink Sheets: MRINF) has entered into a 5 year contract with Aladdin Pharmaceutical to conduct clinical studies related to a new scientific breakthrough treatment for HIV and AIDS at its Hotel de Health medical facility located on
BURLINGAME, Calif., Dec. 4 /PRNewswire/ -- Epimmune, Inc. (Nasdaq: EPMN) and Valentis, Inc. (Nasdaq: VLTS) today announced that Epimmune has licensed Valentis proprietary PINC(TM) gene delivery technology for Epimmune s preventive and therapeutic DNA vaccines in development against the human immunodeficiency virus (HIV
LOS ANGELES, Dec. 2 /PRNewswire/ -- A coalition of South African and U.S. AIDS activists today picketed the Los Angeles consulate of the South African government, demanding the government immediately distribute AIDS treatment shown to drastically reduce infection in newborns. Two hundred newborns today will contract HI
JOHANNESBURG, South Africa , Dec. 1 /PRNewswire/ -- The following press release was issued this morning in South Africa: The South African Ministry of Health and Pfizer Inc. today announced final approval and commencement of the South African Diflucan Partnership Programme, a unique initiative intended to benefit HIV/A
NEW YORK, Dec. 1 /PRNewswire/ -- Every hour of every day, a new young person under age 21 is infected with HIV, and most don t know it until AIDS symptoms strike. To help stem the tide of the youth and HIV epidemic, beginning today -- World AIDS Day -- HIV. Live With It. Get Tested! Week (December 1-9) will reach deep
HALLANDALE, Fla., Dec. 1 /PRNewswire/ -- SMLX (OTC Bulletin Board: SMLX - news), a bio-engineering company, announced today that the company has been served with a one count Information as the result of a government investigation concerning a former product of the company, the Rapid HIV Test Kit. The government contend
LOS ANGELES, Nov. 30 /PRNewswire/ -- Of the 34.3 million people worldwide, 1.3 million children 15 and under are living with HIV and AIDS around the world today according to 1999 estimates by UNAIDS . In the United States , it is estimated that more than 40,000 Americans are infected each year. Half of those infection
WASHINGTON, Nov. 30 /PRNewswire/ -- On the eve of World AIDS Day, Assistant Secretary for Health and Surgeon General David Satcher said that although infections may have fallen, HIV/AIDS still represents a severe and ongoing crisis in America, particularly for men in communities of color. The good news is that HIV infe
INGELHEIM, Germany , Nov. 30 /PRNewswire/ -- Boehringer Ingelheim announced that the Republic of Congo (Congo Brazzaville) is the first country to benefit from the company s offer to provide its anti-HIV drug VIRAMUNE® ( nevirapine ) free of charge for a period of five y
NEW YORK and SAN FRANCISCO, Nov. 30 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) and Netcentives Inc., a leading provider of technology and services for loyalty and direct marketing, are teaming up and challenging the public to help them raise $500,000 for AIDS research with a campaign that awards
GAITHERSBURG, Md., Nov. 30 /PRNewswire/ -- Antex Biologics Inc. (Amex: ANX - news) today announced that it has filed patent applications for two additional novel proteins of Chlamydia trachomatis, the leading sexually transmitted disease in the US and worldwide. These two proteins are being evaluated as vaccine candida
PHILADELPHIA, Nov. 29 /PRNewswire/ -- The workshop will be held at Women s Christian Alliance (WCA), in the main auditorium of the Community Family Center at 1610 N. Broad St., from 11 a.m. to 2 p.m. on December 1, 2000. Lunch and childcare will be provided to those attending. From 2 p.m. to 5 p.m., Hope worldwide will
JODHPUR, India , Nov. 29 /PRNewswire/ -- Located on the eastern border of the Thar Desert, dust storms are common here. However, a different type of storm is about to hit Jodhpur on World AIDS Day, one the city may not be prepared for! Jodhpur is located in northern India state of Rajasthan, where over 50% of the worki
CHICAGO, Nov. 28 /PRNewswire/ -- Chicago s concrete jungle may be worlds away from the African continent, but the two places have something in common. The Windy City is home to the only U.S. company leading the way in HIV/AIDS prevention from a woman s perspective. Women in sub-Saharan Africa and other developing world
COLLEGE STATION, Texas, Nov. 28 /PRNewswire/ -- Research on development of an edible vaccine for AIDS produced from transgenic plants will be funded through an Innovation Grant from the National Institutes of Health and conducted by ProdiGene, a biopharmaceutical and industrial protein company located in College Statio
CARLSBAD, Calif., Nov. 28 /PRNewswire/ -- iMetrikus today announced a partnership with Project Inform, a national non-profit, community-based organization working to end the AIDS epidemic. The partnership with Project Inform will create a co-branded MyHealthChannel Web site for people with HIV/AIDS and their caregivers
LOS ANGELES, Nov. 28 /PRNewswire/ -- In an unprecedented partnership between philanthropic foundations, corporate entities, media outlets and community-conscious organizations, Black Entertainment Television (BET) has announced the creation of Rap-It-Up, a multi-faceted national awareness and call-to-action campaign ad
TARRYTOWN, N.Y., Nov. 28 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced that treatment of HIV positive pediatric patients had begun in a Phase II study of PRO 542, the Company s most clinically advanced HIV inhibitor. The Company also announced the publication of a scientific arti
PITTSBURGH, Nov. 27 /PRNewswire/ -- In conjunction with the 13th annual World AIDS Day, UPMC Health System will offer free HIV testing and counseling from 10 a.m. until 2 p.m. on Friday, Dec. 1. These services will be available at UPMC s HIV treatment arm, the Pittsburgh AIDS Center for Treatment (PACT), located in Sui
MELBOURNE, Australia , Nov. 27 /PRNewswire/-- Virax Holdings Limited (ASX:VHL) announced today ethics committee approval has been received so removing the last hurdle to the start of a human clinical trial of a vaccine to treat people recently infected with HIV. The trial, to be conducted in Melbourne and Sydney, will
NEW YORK, Nov. 27 /PRNewswire/ -- AIDS is the number one cause of death for African-American adults ages 25-44. The Sub-Saharan Africa is the hardest hit in the world, with the greatest concentration of HIV/AIDS. South Africa has the world s highest rate of infection with HIV. It is projected that within the next 5-10
WALTHAM, Mass., Nov. 27 /PRNewswire/ -- Decision Resources, Inc, announces the publication of HIV 2000-Major and Emerging Markets. Increasing prevalence, persistent and resistant infection, and poor adherence continue to make HIV/AIDS a significant pharmaceutical market fraught with unmet needs. In the seven major mark
CAMBRIDGE, Mass., Nov. 27 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - news) announced today that VX-175, an HIV protease inhibitor discovered by Vertex and licensed by Glaxo Wellcome , has entered Phase III clinical trials. VX-175 (also known as GW433908) is a prodrug of the HIV protease inhibit
CINCINNATI, Nov. 22 /PRNewswire/ -- Ethicon Endo Surgery, Vascular Access, a Johnson & Johnson company, embraces the recent passage of the Needlestick Safety and Stick Safety legislation to protect the health of the 8 million healthcare workers in the United States . The bill will require all healthcare faci
CARLSBAD, Calif., Nov. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the trial in Spain of REMUNE(TM) plus antiretroviral drugs in patients infected with HIV continue to its conclusion in May 2001. This d
CARLSBAD, Calif., Nov. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the trial in Spain of REMUNE(TM) plus antiretroviral drugs in patients infected with HIV continue to its conclusion in May 2001. This d
ATLANTA, Nov. 20 /PRNewswire/ -- Serologicals Corporation (Nasdaq: SERO - news) today announced that it has been selected to participate in a Centers for Disease Control and Prevention (CDC) HIV/HCV (Hepatitis C) Risk Factor Study. The CDC, in collaboration with Boston Biomedica, Inc. (Nasdaq: BMII - news) seeks to ana
NEW YORK and LONDON, Nov. 20 /PRNewswire/ -- MTV: Music Television, the world s largest television network, today announced their global programming schedule for World AIDS Day on December 1, 2000. Heading the line-up are two world premieres of original productions, Staying Alive 2, hosted by superstar Ricky Martin and
WASHINGTON, Nov. 16 /PRNewswire/ -- Gospel music artists and leaders joined with the Office of the Surgeon General and the Congressional Black Caucus today to announce a campaign to help address the HIV/AIDS epidemic in the Black community. ONE VOICE: Gospel Artists Respond to AIDS campaign is led by Rev. Yvette Flunde
LAVAL, Quebec, Nov. 15 /PRNewswire/ - BioChem Pharma Inc.(NASDAQ: BCHE - news; TSE: BCH - news) announced today that Trizivir , a new product that combines three anti-HIV medicines into one single tablet, has been approved by the United States Food and Drug Administration. This marks an important advance for dosing
SAN RAFAEL, Calif., Nov. 15 /PRNewswire/ -- The first open label availability in Southeast Asia of Immune Based Therapy (IBT) for humans infected with HIV has been approved by the government of Thailand . Up to 10,000 individuals in this program may receive treatment with REMUNE provided they have certain levels of imm
ST. PAUL, Minn., Nov. 15 /PRNewswire/ -- American Indians and Alaska Natives are experiencing an increasing rate of HIV/AIDS that, if left unchecked, poses a serious health threat that could devastate Native American communities in the United States , a U.S. government official said today. The number of American I
RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire/ -- Trizivir , a new product that combines three anti-HIV medicines into one single tablet, has been approved by the Food and Drug Administration. This marks an important advance for dosing of combination drug regimens. Patients for whom Trizivir is prescribed will now
CAMBRIDGE, Mass., Nov. 15 /PRNewswire/ -- Millions afflicted with chronic illnesses ranging from breast cancer and hepatitis C, to AIDS/HIV and leukemia, now have access to the most comprehensive, reliable clinical trials and treatment information through www.veritasmedicine.com or via premiere health-related sites. Th
MUNICH, GERMANY, Nov. 14 /PRNewswire/ - Stressgen Biotechnologies Corporation (TSE: SSB - news) announced today a ruling from the European Patent Office, Opposition Division (OD) related to European Patent 0419569B1 filed by the Whitehead Institute. This patent represented the earliest filings from Whitehead covering t
PHILADELPHIA, Nov. 14 /PRNewswire/ -- Biosyn, Inc. announced today that SAVVY(TM) vaginal microbicide, a product in development for the prevention of sexually transmitted diseases (STDs), including HIV, was found to be a highly acceptable formulation among women in a Phase I clinical study. SAVVY is a vaginally applied
SAN RAFAEL, Calif., Nov. 13 /PRNewswire/ -- The Clinical Trial using REMUNE(TM) as a treatment for HIV in Thailand has been approved for an additional two years. The Study, known as Protocol 2101B, will become one of the longest scientific examinations of Immune Based Therapy (IBT) for humans infected with HIV. The app
LOS ANGELES, Nov. 10 /PRNewswire/ -- The California Fashion Industry Friends of AIDS Healthcare Foundation (formerly known as California Fashion Industry Friends of AIDS Project Los Angeles) will honor award-winning American designer NICOLE MILLER Wednesday, November 29th at its 11th annual black tie gala and fundraise
BALTIMORE, Nov. 9 /PRNewswire/ -- A new test can tell if cancer patients are likely to respond to the most common drug treatment, according to results of a clinical trial published today in the New England Journal of Medicine. Virco, an international biotechnology company specializing in the diagnosis and management of
LAKEWOOD, N.J., Nov. 9 /PRNewswire/ -- The government of the United States has taken the final step towards making the workplace a safer place for healthcare workers. Between 800,000 and 1 million healthcare workers are accidentally stuck by a needle each year. Once stuck, contracting hepatitis C, HIV, and many other d
WOODS HOLE, MA, Nov. 8 /PRNewswire/ - Stressgen Biotechnologies Corp. (TSE: SSB - news) announces the presentation of preclinical data on the immune response to the HspE7 fusion protein at the International Symposium on Heat Shock Proteins in Biology and Medicine, a scientific conference sponsored by Harvard Medical Sc
SOUTHFIELD, Mich., Nov. 6 /PRNewswire/ -- Southfield-based personal injury law firm Thurswell, Chayet & Weiner is representing former patients of W.A. Foote Memorial Hospital, Inc. in Jackson, Michigan, who were possibly exposed to HIV and Hepatitis during minor outpatient scope procedures. According to the hospita
VICTORIA, BC, Nov. 6 /PRNewswire/ - StressGen Biotechnologies Corp. (TSE: SSB) announced today that it has initiated patient treatment in a Phase III clinical trial to investigate HspE7 as a novel immunotherapeutic for anal dysplasia (AIN) caused by the human papilloma virus (HPV). HPV is one of the most common sexuall
KANSAS CITY, Mo., Nov. 6 /PRNewswire/ --AVAX Technologies, Inc. (Nasdaq: AVXT) today announced that it has been granted U.S. Patent No. 6,140,114 from the U.S. Patent and Trademark Office entitled Defective viral vaccine particles obtained in vivo or ex vivo. David Klatzmann, M.D., Ph.D. and Jean-Loup Salzmann, M.D., P
PHILADELPHIA, Nov. 2 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said that results of a Phase II study of the investigational drug Ampligen(R) would be first presented at the American Society of Microbiology Conference in Memphis, Tennessee, on November 3 and 4, 2000. The U.S. based monotherapy clinic
NEW YORK, Nov. 2 /PRNewswire/ -- Advanced Viral Research announced today that new data on Reticulose, their flagship product for the treatment of HIV and other viral diseases will be presented at the National AIDS Treatment Advocacy Conference held by the National Minority AIDS Council in Dallas Texas, November 9th to
CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it had initiated binding arbitration proceedings in a disagreement with the University of California San Francisco (UCSF) and a member of its faculty, Dr. James Kahn. The principle basis for the arbitration is
DURHAM, N.C., Oct. 30 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today reported on the anti-hepatitis B virus (HBV) activity of Coviracil(R) (emtricitabine) in a Phase I/II dose-selection trial involving patients chronically infected with HBV. The data are being presented at the 51st Annual Meeting o
LOS ANGELES, Oct. 27 /PRNewswire/ -- The African-American AIDS Policy and Training Institute (AAAPTI), the nation s first and only think tank dedicated to studying the policies and science of AIDS among African-Americans, will christen new headquarters at a grand opening ceremony here today. The new facility includes t
ANCHORAGE, Alaska, Oct. 27 /PRNewswire/ -- The Alaska Housing Finance Corporation (AHFC) will receive $572,600 to continue providing housing services for persons with HIV/AIDS in cooperation with its sponsor, the Alaskan AIDS Assistance Association (Four A s). Alaska was one of 17 states recently awarded $23.6 million
MELBOURNE, Australia , Oct. 26 /PRNewswire/ -- Sydney researchers at the University of New South Wales (UNSW) have invented a new cancer drug that starves tumours instead of poisoning them. Melbourne pharmaceutical company IDT Australia Ltd will manufacture the drug and work to capture the commercial benefit for Austra
ALAMEDA, Calif., Oct. 26 /PRNewswire/ -- On October 26, 2000 the U.S. Senate joined the fight to protect America s health care workers by passing a U.S. House of Representatives bill, H.R. 5178, the Needlestick Safety and Prevention Act of 2000. H.R. 5178 has strong bipartisan support and unanimously passed both chambe
WASHINGTON, Oct. 26 /PRNewswire/ -- Members of the nation s largest health care union say passage of bipartisan legislation in the U.S. Senate today will protect health care workers from deadly needlestick injuries that can spread HIV and hepatitis C. This bill will save the lives of thousands of health care workers,
GLASGOW, Scotland, Oct. 26 /PRNewswire/ -- Data presented today at the 5th International Congress on Drug Therapy in HIV Infection for the first time revealed the mutations in the genetic code of HIV that make the virus resistant to the HIV drug, d4T ( stavudine ).
WASHINGTON, Oct. 25 /PRNewswire/ -- Gender plays a major role in the way we experience and respond to various treatments for pain, addiction, and sexually transmitted diseases, according to recent research. These and other emerging trends in sex-based research will be presented and discussed at the Society for Women s
BALTIMORE, Oct. 24 /PRNewswire/ -- A new test for the simultaneous determination of levels of all the HIV drugs currently in widespread use is now available from Virco. The test, named VircoPK(TM) is rapid and more accurate and reliable than other tests for measuring drug levels. It can be used in conjunction with Virc
GLASGOW, Scotland, Oct. 24 /PRNewswire/ -- Data presented at the Fifth International Congress on Drug Therapy in HIV Infection in Glasgow show that to date, patients new to HIV therapy have not developed genotypic resistance to Abbott Laboratories (NYSE: ABT) protease inhibitor (PI), Kaletra
NEW YORK, Oct. 24 /PRNewswire/ -- The M.A.C. AIDS Fund donated $250,000 to UNDP to support seven grassroots projects helping people living with HIV/AIDS and promoting HIV/AIDS awareness in six southern African countries. John Demsey, President of M.A.C. Cosmetics, announced the donation at the Fourth Annual Race Agains
LOS ANGELES, Oct. 24 /PRNewswire/ -- The American Academy of HIV Medicine (AAHIVM) reached an important milestone this month. As of October, more than 500 physicians representing approximately 100,000 HIV/AIDS patients nationwide have joined the new organization. AAHIVM was launched in January by a group of physicians
NEW YORK, Oct. 24 /PRNewswire/ -- The Adolescent AIDS Program at Montefiore Medical Center today convenes Gettin Busy Youth and HIV: A Conference and Call to Action for Providers and Youth in New York City. Featuring a key note address by New York State Health Commissioner Antonia Novello, MD, DPH, this multidisciplina
NEW YORK, Oct. 23 /PRNewswire/ -- New York City Marathon Runner Renee Stene is leading a drive to support AIDS orphans in Africa and the Francois-Xavier Bagnoud s GLOBAL ACTION FOR ORPHANS CAMPAIGN by signing up pledges for her run on November 5th. Renee s efforts will help raise awareness in the world s biggest city o
CAMBRIDGE, Mass., Oct. 23 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that its collaborator, Glaxo Wellcome , has received approval from the European Commission to market the HIV protease inhibitor (PI) Agenerase (amprenavir), in all 15 countries of th
BRISBANE, Calif., Oct. 23 /PRNewswire/ -- VaxGen (Nasdaq: VXGN) announced today that it is now one year away from its first opportunity to determine if its preventive HIV/AIDS vaccine is effective. The milestone was reached when VaxGen s Phase III clinical trials received a positive safety review that allows the trials
GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- New data released today at the 5th International Congress on Drug Therapy in HIV Infection in Glasgow, Scotland, have shown that patients stay significantly longer on Viracept (nelfinavir)-based initial HAART regimens than on indinavir-based initial HAART regimens. The data al
GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- New study findings show that 85% (23/27) of HIV/AIDS patients who added MARINOL(R) (dronabinol) to their current antiretroviral therapy had a 50% improvement in symptoms of nausea and vomiting. MARINOL is indicated as an appetite stimulant for patients with AIDS-associated was
GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- Data presented today at the 5th International Congress on Drug Therapy in HIV Infection identified and discussed new drug-specific, biological cut-off values developed by Virco for its HIV drug resistance tests. These will tell clinicians instantly whether their patient s viru
GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- F. Hoffmann-La Roche , makers of the anti-HIV agents Fortovase(R) (saquinavir) and Viracept (R) (nelfinavir*), has called on developers of other protease inhibitors to agree to a world-wide standardisation of measures of d
GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- Roche has announced the results of in vitro laboratory experiments showing that the Roche HIV protease inhibitor (PI) saquinavir is more potent than the new PI, lopinavir . The study, presented at the 5th International Congress on Drug Therapy in HIV Infection in Glasgow, test
NEW YORK, Oct. 20 /PRNewswire/ -- Further clinical research into HIV drug resistance along with aggressive advocacy by growing numbers of AIDS activists has created a consensus amongst many prominent AIDS treatment activists and clinicians that Riticulose, the flagship product of Advance Viral Research may be the best
NEW YORK, Oct. 19 /PRNewswire/ -- Seth Berkley, MD, President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), issued the following the statement in response to the publication in Science of a study showing promising results in monkeys for a DNA-based AIDS vaccine augmented with interleu
MINNEAPOLIS and LOS ANGELES, Oct. 19 /PRNewswire/ -- The nation s largest HIV medical services organization today opened its first on-site pharmacy at a gala ceremony at the downtown Los Angeles AHF Healthcare Center. This event launches an innovative effort between two diverse healthcare industry leaders: MedManagemen
WARWICK, R.I., Oct. 19 /PRNewswire/ -- Hope for African Children, a partnership of international development and relief organizations, has received a $1 million grant from the Bill & Melinda Gates Foundation to develop a pioneering pan-African initiative designed to deliver essential services and support to the mil
WASHINGTON, Oct. 18 /PRNewswire/ -- U.S. Housing and Urban Development Secretary Andrew Cuomo today awarded $23.6 million to programs in 17 states to provide housing and related support services to more than 2,700 low-income people with HIV/AIDS and their families. The grants are part of HUD s Housing Opportunities for
NEW YORK, Oct. 18 /PRNewswire/ -- Teenagers are bombarded with images of sex on a daily basis. Whether it be television, movies, music, or magazines, the joy of sex is often glorified while the consequences are rarely addressed. Yet what teenagers need to know is that most sexually transmitted diseases are difficult to
PHOENIX, Oct. 18 /PRNewswire/ -- Verizon Wireless today announced that it is the official wireless sponsor for the 13th annual AIDS Walk Arizona to be held on Sunday, Nov. 5. As part of its sponsorship, customers who register for the walk by Oct. 25 at any Verizon Wireless store will receive an additional 100 free minu
TARRYTOWN, N.Y., Oct. 17 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced that it had been awarded approximately $6.0 million from the National Institutes of Health (NIH) for the development of novel therapies and vaccines for HIV infection. The awards consist of a research grant fo
DENVER, Oct. 16 /PRNewswire/ -- Weight loss and HIV wasting have a direct impact on survival in cancer and HIV/AIDS patients. Data supporting these findings, as well as methods for early intervention to prevent weight loss, were discussed here today at a symposium, Evidence-Based Management of Disease-Related Weight Lo
NEW YORK, Oct. 16 /PRNewswire/ -- The FDA is holding a meeting today in Washington D.C. to explore the problems that have surrounded the regulatory review of immune based therapies for HIV. Over the past two years AIDS Treatment Activists from around the country have advocated within the FDA for a revision of regulator
NEW YORK, Oct. 16 /PRNewswire/ -- A much needed and long overdue meeting has been scheduled for Oct. 16 by the FDA Antiviral Committee to discuss Immune Based Therapies. This much anticipated effort by the FDA provides an encouraging signal to the pharmaceutical industry and biotech companies that meaningful progress i
NEW YORK, Oct. 16 /PRNewswire/ -- Over the past 14 months, AIDS treatment activists, many of whom are members of The HIV Immune Based Therapy Working Group have placed pressure on the Food and Drug Administration regarding the FDA process, procedures and review of immune based therapies for the treatment of HIV disease
LAKEWOOD, N.J., Oct. 13 /PRNewswire/ -- Healthcare workers might not have to fear losing their lives saving others, but it is up to the government of the United States to make it happen. Between 800,000 and 1 million healthcare workers are accidentally stuck by a needle each year. Once stuck, contracting hepatitis C, H
BOSTON, Oct. 12 /PRNewswire/ -- The Commission on Macroeconomics and Health (CMH) will expand its work in improving public health with a recent gift of $1 million from the Bill & Melinda Gates Foundation. The CMH, launched by the Director General of the World Health Organization in January 2000, studies the intrica
NEW YORK, Oct. 12 /PRNewswire/ -- On Monday, October 23, 2000, the United Nations Development Programme (UNDP) will hold its Fourth Annual Race Against Poverty Awards at the United Nations General Assembly from 6:00 p.m. to 8:00 p.m. Grammy Award-winning superstar and MAC Cosmetics VIVA GLAM III spokesperson Mary J. Bl
EDINBURGH, Scotland, Oct. 11 /PRNewswire/ -- University of Edinburgh scientist, Peter Simmonds, Ph.D., MRCPath, today received a Consortium for Plasma Science Fellowship to support his ground-braking research on the evolution, epidemiology, and potential pathogenicity of a controversial group of novel, human blood born
CHICAGO, Oct. 11 /PRNewswire/ -- AIDS is an invisible issue in the 2000 presidential campaign, with neither candidate articulating a vision or strategy for combating an epidemic labeled by the US government and the United Nations as threats to human security. So says the International Association of Physicians in AIDS
BANGKOK, Thailand , Oct. 9 /PRNewswire/ -- The Global Alliance for TB Drug Development, a public-private partnership for the discovery of new drugs to treat one of the world s deadliest infectious diseases, was inaugurated today at the International Conference on Health Research for Development by its stakeholders from
LOS ANGELES, Oct. 9 /PRNewswire/ -- Californians facing HIV will soon receive state-funded health insurance coverage thanks to a four-year AIDS Healthcare Foundation (AHF) effort now endorsed by Governor Gray Davis. Medi-Cal will soon abandon AIDS-related disability as a requirement for HIV treatment for the poor, sai
ATLANTA, Oct. 4 /PRNewswire/ -- Remembering the past and building the future was the theme of the US Conference on AIDS 2000 (USCA) held October 1- 4, 2000 in Atlanta, Georgia. With over 3,300 participants, it was the largest AIDS conference held in the US and by all accounts one of the most diverse. Sponsored by Washi
WASHINGTON, Oct. 3 /PRNewswire/ -- The National Council of Negro Women (NCNW) today released A Devastating Tragedy: AIDS in Africa, a detailed report on the challenges that HIV/AIDS is posing for nations in sub-Saharan Africa. NCNW was spurred to action by the horrifying statistics that one out of every five people in
NEW YORK, Oct. 2 /PRNewswire/ -- Joy shines bright as MAC Cosmetics continues its fight against HIV and AIDS through the company s Kids Helping Kids Cards program. The cards, painted by children living with HIV/AIDS, raise money for other children living with HIV/AIDS. Colorful, all season cards illuminate lives and se
SAN RAFAEL, Calif., Sept. 29 /PRNewswire/ -- Trinity Medical Group USA, Inc. announces the publication of results of a human clinical study of its Immune Based Therapy for the treatment of HIV (HIV-1 immunogen or Remune(TM)) following scientific peer-review. The study, entitled A Double-Blind, Adjuvant-Controlled Trial
NEW YORK, Sept. 28 /PRNewswire/ -- At today s New York-based meeting of the International AIDS Society entitled Current Challenges in HIV Disease held at the Hilton Hotel, over 2000 clinicians, research scientists and other health care practitioners were greeted by a major announcement of a new clinical initiative to a
SAN DIEGO, Sept. 27 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced clearance from the South African Medicines Control Council (MCC) for the Company to initiate additional clinical studies in HIV infected patients with HE2000, its lead investigational drug candidate. These new studies i
CINCINNATI, Sept. 26 /PRNewswire/ -- For the second straight year, Anthem Blue Cross and Blue Shield (Anthem) has received the Gold HERA Award for helping improve women s and children s health. Presented annually, this national award is co-sponsored by the National Managed Health Care Congress (NMHCC) and Wyeth-Ayerst
BONN, Germany , Sept. 21 /PRNewswire/ -- An AIDS vaccine candidate designed specifically for Africa and manufactured in Germany has been approved for human testing. Wayne Koff Ph.D., Vice President for Research and Development of the International AIDS Vaccine Initiative (IAVI), announced today that the Medicines Contr
BONN, Germany , Sept. 21 /PRNewswire/ -- An AIDS vaccine candidate designed specifically for Africa and manufactured in Germany has been approved for human testing. Wayne Koff Ph.D., Vice President for Research and Development of the International AIDS Vaccine Initiative (IAVI), announced today that the Medicines Contr
BRISBANE, Calif., Sept. 20 /PRNewswire/ -- The same principle used to develop the first successful herpes vaccine, whose efficacy data were unveiled this week, was also used to develop a preventive HIV/AIDS vaccine currently in the final stage of clinical testing. Both vaccines were produced by cloning key proteins on
SAN DIEGO, Sept. 20 /PRNewswire/ -- Researchers at The University of Wisconsin, in collaboration with Epimmune Inc. (Nasdaq: EPMN), reported new insight into how the immune system controls the AIDS virus in a non-human primate model. These findings may facilitate the development of a preventive vaccine against the huma
TORONTO, Sept. 20 /PRNewswire/ -- Results presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) indicate that the VirtualPhenotype(TM), Virco s new automated HIV drug resistance test, can predict response to therapy from genetic information with comparable results to a pan
TORONTO, Sept. 19 /PRNewswire/ -- The following press release was issued today by Meditech Media: Roche Pharmaceuticals today reported results from a survey that showed no difference in adherence to therapy between twice-daily (BID) and once-daily (QD) dosing regimens, among people living with HIV. The survey was desig
TORONTO, Sept. 19 /PRNewswire/ -- A study that evaluated dosage adjustments of the protease inhibitor (PI) Agenerase (R) ( amprenavir ) capsules in HIV patients treated with efavirenz or nevirapine , antiretroviral (ART) agents known to
BURLINGTON, N.C., Sept. 19 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)), the nation s leading provider of HIV tests, today presented its latest findings on HIV viral load trends in the United States at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
VANCOUVER, Sept. 19 /PRNewswire/ - Data on a new orally-administered drug candidate with the potential to block HIV from entering and infecting healthy T-cells was presented today by AnorMED Inc. (TSE: AOM ) at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto. Michael J. Abra
TORONTO, Sept. 19 /PRNewswire/ -- Updated NARVAL data presented yesterday during the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) showed a better long term virologic benefit to HIV-infected patients who received HIV drug resistance genotype testing over those patients who received Stand
TORONTO, Sept. 19 /PRNewswire/ -- Pharmacokinetic data presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy suggest that, when selective serotonin reuptake inhibitors (SSRIs) are used at the same time that patients with HIV infection are receiving DuPont Pharmaceuticals
SAN FRANCISCO, Sept. 19 /PRNewswire/ -- The first ever HIV prevention television commercial aimed at HIV positive gay/bi men and transgenders has been banned from the airwaves by KGO-TV. KGO Channel 7 is the San Francisco ABC/Disney affiliate. The spot, HIV STOPS WITH ME, is part of an innovative new campaign featuring
CARLSBAD, Calif., Sept. 19 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that REMUNE(TM) (HIV-1 Immunogen), an investigational therapeutic vaccine for the treatment of HIV infection, will be tested as part of a clinical trial entitled QUEST. Glaxo Wellcome (NYSE: GLX) is the main sp
BALTIMORE, Sept. 19 /PRNewswire/ -- Virco Lab Inc., the U.S. subsidiary of Virco, has successfully passed College of American Pathologists (CAP) and New York State inspections. Accreditation by these bodies means Virco can now provide its advanced HIV drug resistance monitoring services to U.S. physicians directly from
MECHELEN, Belgium , Sept. 19 /PRNewswire/ -- Tibotec, an emerging international pharmaceutical company focused on the development of new drugs for HIV/AIDS today presented very positive results on one of its lead anti-HIV drugs, R165335-TMC125, at the 40th Interscience Conference on Antimicrobial Agents and Chemotherap
TORONTO, Sept. 18 /PRNewswire/ -- In a study of 274 antiretroviral-experienced HIV patients, researchers today reported that genoptypic testing is of significant benefit as compared to standard of care (SOC) treatment in a variety of drug-experienced populations. Results from the six-month, randomized, prospective, mul
TORONTO, Sept. 18 /PRNewswire/ -- Preliminary study results showed Crixivan (R) ( indinavir sulfate) administered as an investigational twice-daily 800-mg dose with a low dose of ritonavir(A) (100 mg) suppressed levels of HIV to below the limits of detection in patients with no prior protease in
TORONTO, Sept. 18 /PRNewswire/ -- Virco today announced the availability of online access to their HIV drug resistance tests via a new service named VircoTrack(TM), the world s first pharmacogenomic service on the Internet. With VircoTrack(TM), healthcare professionals have secure access to status reports on tests that
TORONTO, Sept. 18 /PRNewswire/ -- New findings show that 86% of patients (63 out of 73) with undetectable levels of HIV who switched treatment from a protease inhibitor (PI)-based regimen to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen maintained suppression of HIV (Amplicor(R) assay; 200 copi
TORONTO, Sept. 18 /PRNewswire/ -- Data at 40 weeks from an ongoing Phase III study (M98-863) presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy showed a significantly higher percentage of patients new to HIV therapy taking Abbott Laboratories protease inhibitor (PI), KaletraTM
PHILADELPHIA, Sept. 18 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC), a local non-profit organization and major funder of support services to individuals with HIV/AIDS, today announced a new health care initiative for the HIV/AIDS community. TPAC was joined today by Philadelphia Health Commissioner Walter Tso
DURHAM, N.C., Sept. 18 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) and Abbott Laboratories (NYSE: ABT) today announced the preliminary results of a Phase I/II trial in which DAPD produced impressive decreases in the viral loads of a cohort of five HIV-infected patients who were failing their antiviral
TORONTO, Sept. 18 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today announced that it has initiated an additional trial of the investigational drug capravirine, for the treatment of HIV infection, as part of combination therapy in people who have failed previous therapy. Capravirine will be investigated in a double-b
TORONTO, Sept. 18 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that a triple drug cocktail of PRO 542, PRO 140 and T-20 acts synergistically to potently block HIV infection in vitro. Each of these drugs inhibits a different step in the sequence of events leading to the entry of HIV into targ
TORONTO, Sept. 17 /PRNewswire/ -- The first-year costs to manage a single symptom of an increasingly common complication associated with HIV/AIDS therapy could range from $410 to $7,369 per patient, according to a pharmacoeconomic modeling study presented here today at the 40th annual meeting of the Interscience Confer
TORONTO, Sept. 17 /PRNewswire/ -- Data presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy indicate that the combination of DuPont Pharmaceuticals (NYSE: DD) Sustiva (TM) ( efavirenz ), d4T (
TORONTO, Sept. 17 /PRNewswire/ -- Data presented today indicate that DuPont Pharmaceuticals (NYSE: DD) anti-HIV drug Sustiva (TM) ( efavirenz ), when substituted for a protease inhibitor, successfully maintains viral load suppression (less than 50 copies/mL) in patients who had already achieved
TORONTO, Sept. 17 /PRNewswire/ -- According to 84 week results from a clinical trial presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), SUSTIVA, when used with ZERIT and EPIVIR, was a well-tolerated three-drug regimen effective in reducing viral load in treatment-naive
OAKLAND, Calif., Sept. 15 /PRNewswire/ -- Wishing healthy, productive and long lives to Oakland residents with AIDS, basketball great Magic Johnson today dedicated a new HIV clinic in Oakland, California, named in his honor and operated by the AIDS Healthcare Foundation (AHF). (Photo: http://www.newscom.com/cgi-bin/prn
LOS ANGELES, Sept. 15 /PRNewswire/ -- Governor Gray Davis this week signed landmark legislation ordering California HMOs to provide AIDS specialists for patients infected with HIV. The new law by Assemblyman Martin Gallegos gives patients a legal right to obtain care from physicians who have demonstrated expertise in
ABBOTT PARK, Ill., Sept. 15 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today it received accelerated U.S. Food and Drug Administration ( FDA ) approval to market its antiretroviral, Kaletra (TM) ( lopinavir /
TORONTO, Sept. 14 /PRNewswire/ -- Physicians who treat people living with HIV are less conclusive about the causes of lipodystrophy, a condition that affects some people living with HIV. Seventy-one percent of physicians believe that the causes of lipodystrophy are multifactorial, compared to 53% who recalled believing
SAN FRANCISCO, Sept. 13 /PRNewswire/ -- The first ever HIV prevention television commercial aimed at HIV positive gay/bi men and transgenders will be premiered September 14th, 2000 in San Francisco. HIV prevention messages up until now have not targeted those men who already know they are HIV positive. As part of an in
WASHINGTON, Sept. 13 /PRNewswire/ -- To help stem the HIV/AIDS epidemic in communities where the virus is spreading fastest, pharmaceutical leader Glaxo Wellcome today announced the nationalization of a peer-to-peer approach modeled after the focused intervention concept utilized at the OASIS clinic in the Watts neighb
PHILADELPHIA, Sept. 12 /PRNewswire/ -- MEE (Motivational Educational Entertainment) Productions Inc., an international communications and marketing firm specializing in urban issues, has been selected by the U.S. Centers for Disease Control and Prevention (CDC) to develop HIV testing campaigns and communications materi
DURHAM, N.C., Sept. 11 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that researchers from the Agence Nationale de Recherche sur le SIDA (ANRS) in France presented the one-year results of a pilot study of a once-a-day HAART (highly active antiretroviral therapy) regimen, combining Covira
ARLINGTON, Va., Sept. 9 /PRNewswire/ -- The following is being issued by the Chronic Illness Research Foundation: Scientists today called for a moratorium on all HIV vaccine research and clinical trials until the mechanism of AIDS is further elucidated. The official call for a moratorium will appear in the October 2000
SAN FRANCISCO, Sept. 8 /PRNewswire/ -- AIDS Treatment News, a twice-monthly newsletter published continuously for 14 years, devotes its current issue #350 to the effect of modern treatment on survival of persons with HIV infection or AIDS. Designed for physicians to give to patients when necessary, but available free t
NEW ORLEANS, Sept. 8 /PRNewswire/ -- Malte Schutz, MD (Illinois Masonic Medical Center, Chicago, IL) and William Owen, MD (California Pacific Medical Center, San Francisco, CA) reported a study today which evaluates the durability of anti-HIV therapy including RESCRIPTOR(R) ( delavirdine mesylate) tab
SAN DIEGO, Aug. 15 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) announced today that it has been awarded a $3.8 million grant from the Integrated Preclinical/Clinical Program (IPCP) of the National Institutes of Health (NIH), Division of AIDS, for the development of a new vaccine approach to treat people infected with
WEST BRIDGEWATER, Mass., Aug. 11 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII) announced today the signing of a Cooperative Research and Development Agreement with the National Institutes of Health Clinical Center (NIHCC) to develop applications of BBI s proprietary Pressure Cycling Technology (PCT) for clinica
NEW YORK, Aug. 11 /PRNewswire/ -- AIDS treatment activists from ACT UP Brooklyn, Women s AIDS Research and the International Immune Based Therapy Working Group have joined together to lobby delegates to make the availability of developing HIV therapies a campaign issue. The necessity to provide the FDA
DURHAM, N.C., Aug. 10 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today its continued development of Coactinon in support of an NDA filing. Coactinon is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. This action follows notification from the
TARRYTOWN, N.Y., and PRINCETON, N.J., Aug. 10 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Pharmacopeia, Inc. (Nasdaq: PCOP) have announced the initiation of two new collaborative programs to discover orally active antiviral agents. The target for the first program is the HIV envelope glycoprotein
HOUSTON, Aug. 9 /PRNewswire/ -- Thousands of Houston residents are expected to be tested for HIV and attend an all-star R&B and gospel concert on Get Tested Days, Aug. 10 and Aug. 11. The local campaign was organized by a coalition including individuals from the City of Houston s Health Dept., the mayor s office, t
WASHINGTON, Aug. 8 /PRNewswire/ -- Family Research Council s Robert Maginnis, vice president for national security and foreign affairs, returned Monday from investigating the AIDS problem in South Africa . AIDS is causing the desolation of human life in South Africa, yet the U.S. is perpetuating the problem by funding
BALTIMORE, Aug. 8 /PRNewswire/ -- The Centers for Disease Control (CDC) has awarded a major contract to Virco to conduct the testing for its pivotal survey of transmission of drug-resistant strains of HIV in the U.S. The total contract is worth over $400,000. This is the first major contract with the U.S. government ag
WASHINGTON, Aug. 4 /PRNewswire/ -- For the first time, Diane Mawyer, RN, is telling the traumatic story of her exposure to hepatitis C (HCV) through a needlestick injury on the job, and her subsequent fight for life through three organ transplants, at a meeting here of the Frontline Healthcare Workers Safety Foundation
ABBOTT PARK, Ill., Aug. 4 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) Kaletra , formerly ABT-378/r, Early Access Program now has availability for more patients. Kaletra is Abbott s investigational HIV protease inhibitor currently in Phase III clinical trials. In January, Abbott expanded its Early Access program cr
CHICAGO, Aug. 3 /PRNewswire/ -- The Vascular Access Business unit of Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, today announced it will sponsor the American Association of Nurse Anesthetists (AANA) Party with a Purpose charity event, Sunday, August 6, from 8 p.m. to midnight, at the Hyatt Regency, Chi
WATERTOWN, Mass., Aug. 1 /PRNewswire/ -- V.I. Technologies, Inc. (VITEX) (Nasdaq: VITX) announced today that it has signed an agreement with the American National Red Cross (ANRC) for a six year extension of its exclusive distribution agreement for virally-inactivated transfusion plasma products. Notably, the extension
PHILADELPHIA, Aug. 1 /PRNewswire/ -- Pat Funderburk Ware, president and CEO of the Preserving Family Well-Being Foundation, will speak at the Republican National Convention this evening. The evening s program will be dedicated to Governor George W. Bush s theme of Strength and Security With a Purpose: Safe in Our Homes
MINNEAPOLIS, July 31 /PRNewswire/ -- Abbott Northwestern Hospital is searching for people with HIV who are willing to try an experimental treatment using Interleukin-2, a substance that has been licensed to fight certain cancers. Interleukin-2 is a naturally occurring protein that stimulates the body s immune response.
NEW YORK, July 27 /PRNewswire/ -- The close of the 13th World AIDS Conference has led to an increased emphasis in the pursuit of effective methods of treating drug resistant HIV. The 13th World AIDS Conference has left us with definitive evidence that the need exists for effective therapies to treat resistant HIV. The
CHICAGO, July 27 /PRNewswire/ -- Last evening, Reverend Jesse L. Jackson, Sr. hosted a Town Hall Forum on the HIV/AIDS epidemic in the African American community as part of the Rainbow/PUSH Coalition s Annual Convention. The event, Ending the Silence: Ending the Epidemic , was broadcast live nationally on the Black Ent
NEW YORK, July 26 /PRNewswire/ -- With the close of the 13th International AIDS Conference, a coalition of leading AIDS Treatment activists are demanding better access to Reticulose, a lipoprotein-nucleic acid complex manufactured by Advanced Viral Research that has shown promise in the treatment of many of the symptom
TARRYTOWN, N.Y., July 20 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the publication of a scientific article describing the initial clinical trial of PRO 542, the Company s most clinically advanced HIV inhibitor. In the study, a single dose of PRO 542 demonstrated measurable antiviral
BUTTE, Mont., July 20 /PRNewswire/ -- Maternal Life International (MLI), a Butte-based non-profit world health care and disease prevention organization that focuses on women and children, has been awarded a $273,000 grant by Bristol-Myers Squibb (NYSE: BMY), a global health and personal care company, to implement a par
LONDON, July 20 /PRNewswire/ -- The DNA manufacturing division of Cobra Therapeutics, a subsidiary of the UK emerging pharmaceutical company ML Laboratories, has just received regulatory approval to produce DNA for the clinical trials of a novel DNA vaccine against HIV subtype A, which is the most common strain in many
CHICAGO, July 19 /PRNewswire/ -- With U. S. Centers for Disease Control statistics showing increasing sexually transmitted disease (STD) including HIV/AIDS infection among American women, public health officials and policymakers are examining ways to help women protect themselves and their families from the dreaded dis
What: Ribbon Cutting & Reception, Grand Opening of new community AIDS facility, Earvin Magic Johnson, Jr. Clinic at AHF s Healthcare Center/Oakland When: THURSDAY, JULY 20th 11a.m. - 1p.m. Program begins: 11:30am, Ribbon Cutting: 12 noon Where: Earvin Magic Johnson, Jr. Clinic at AHF s Healthcare Center/Oakland (ad
LAVAL, Quebec, July 18 /CNW - PRN/ -BioChem Pharma Inc. (NASDAQ: BCHE; TSE: BCH) announced today that the European Union s Committee for Proprietary Medicinal Products (CPMP) has recommended the approval of Trizivir , Glaxo Wellcome s new triple combination tablet developed for the treatment of HIV-infected adults, in
WILMINGTON, Del., July 17 /PRNewswire/ -- Data recently presented suggest that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and the experimental protease inhibitor ABT-378/
WILMINGTON, Del., July 17 /PRNewswire/ -- Data presented at a major medical meeting last week demonstrate that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), a non-nucleoside reverse transcriptase inhibitor (NNRTI), may provide an effective and safe alternative to long-term pro
WILMINGTON, Del., July 17 /PRNewswire/ -- Data recently presented indicate that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), when substituted for a protease inhibitor, successfully maintained viral load suppression (less than 50 copies/mL) in patients who had already achieved
NEW YORK, July 14 /PRNewswire/ -- In a POZ magazine cover story, Nushawn Williams, the young African American the media called The AIDS Monster in 1997, goes on record for the first time saying that he didn t know he had HIV when he had sex with 28 women in New York s Chattaqua County. Williams is currently serving fou
CARLSBAD, Calif., July 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that Trinity Medical Group, the Company s licensee for development of REMUNE in Southeast Asia, has informed the Company that follow-up data from the Phase II clinical trial conducted in Thailand were pre
DURBAN, South Africa , July 14 /PRNewswire/ -- More than 20,000 people from around the world logged on to webcast.aids2000.com during the first days of the XIII International AIDS Conference held this week in Durban, South Africa. The conference, which is the largest international HIV meeting, takes place once every tw
DURBAN, South Africa , July 13 /PRNewswire/ -- Two studies using Virco s HIV drug resistance monitoring systems as part of the UNAIDS Drug Access Initiative have revealed the development of high levels of resistance in African countries pioneering the use of antiretrovirals on this continent. The study, conducted in
DURBAN, South Africa , July 13 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported no difference in adherence to therapy among a survey of people living with HIV that was designed to compare adherence rates between either the HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) twice daily (BID) or non-nuc
DURBAN, South Africa , July 13 /PRNewswire/ -- Findings from the Atlantic study indicate that VIRAMUNE(R) ( nevirapine ) + two nucleoside analogues has shown similar efficacy to indinavir * + two nucleoside analogues.
DURBAN, South Africa , July 13 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported a study in healthy volunteers indicating that an investigational once-daily dosing (QD) of the HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) in combination with small doses of
DURBAN, South Africa , July 13 /PRNewswire/ -- VaxGen Inc. s (Nasdaq: VXGN) leadership in developing worldwide HIV/AIDS vaccines was highlighted this week at the XIII International AIDS Conference as researchers presented scientific updates on the company s late-stage clinical trials. (Photo:http://www.
DURBAN, South Africa , July 13 /PRNewswire/ -- Two studies using Virco s HIV drug resistance monitoring systems as part of the UNAIDS Drug Access Initiative have revealed the development of high levels of resistance in African countries pioneering the use of antiretrovirals on this continent. The study, conducted in
CARLSBAD, Calif., July 13 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that preliminary interim clinical results from an ongoing Phase II trial in Spain indicate that functionally active cytotoxic T lymphocytes (CTL) or killer T cells appear to be stimulated in HIV-positive individuals
DURBAN, South Africa , July 13 /PRNewswire/ -- VaxGen Inc. s (Nasdaq: VXGN) leadership in developing worldwide HIV/AIDS vaccines was highlighted this week at the XIII International AIDS Conference as researchers presented scientific updates on the company s late-stage clinical trials. In nine separate presentations
NAPA VALLEY, Calif., July 12 /PRNewswire/ -- On August 15, 2000, the Glass Chapel at the di Rosa Art Preserve in Napa Valley will host a dusk-to-dawn puja (sanskrit for prayer ceremony ) in remembrance of those who have died of AIDS and honoring those living with HIV/AIDS. The once in a lifetime event, according to the
FRAMINGHAM, Mass., July 12 /PRNewswire/ -- Researchers from the University of Rochester reported today on a human study demonstrating that Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA) proprietary vaccine adjuvant, QS-21, and substantially reduced amounts of the HIV gp120 antigen, produced high levels of antibodies in
DURBAN, South Africa , July 12 /PRNewswire/ -- Data presented today at the 13th International Conference on AIDS from Virco s Antivirogram(TM) resistance test indicate that a second generation of HIV drugs may be highly active against the strains of HIV found in developing countries. The phenotypic test used in the stu
- Groundbreaking project aimed at reducing the rate of mother-to-child transmission of HIV at the Perinatal HIV Research Unit at the University of the Witwatersrand. - Bristol-Myers Squibb Company s Secure the Future program to provide grant of US$700 thousand (R4,2 million).Epitope, Inc. contributing $50,000 (R300 tho
DURBAN, South Africa , July 12 /PRNewswire/ -- Study results presented today at the 13th International AIDS Conference in Durban, South Africa show a VIRAMUNE(R) ( nevirapine , NVP) treatment combination suppressed HIV in the blood for up to one year in patients with advanced HIV disease and high baseline levels of HIV
DURBAN, South Africa , July 12 /PRNewswire/ -- A study evaluating VIRAMUNE(R) ( nevirapine ) versus ZDV + 3TC * for the prevention of mother-to- child transmission (MTCT) of HIV was presented at the 13th International AIDS Conference.
DURBAN, S.A., July 12 /PRNewswire/ -- A $1 million grant from the Bill & Melinda Gates Foundation has been awarded to Childreach, the US member of PLAN International - one of the world s largest child-focused development organizations - to develop an initiative to help the millions of African children affected by H
DURBAN, South Africa , July 12 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announced today that the Bill & Melinda Gates Foundation has awarded a $15 million grant directed to its newest global initiative, the Call to Action Project, to reduce mother-to-infant HIV transmission globally. This gift
WALTHAM, Mass., July 11 /PRNewswire/ -- In the early 1980s, when HIV was first identified as the causative agent of AIDS, no one could have predicted the impact this disease would have. In the past two decades, more than 50 million people have become infected and roughly 17 million have died. In some countries, as many
ABBOTT PARK, Ill., July 11 /PRNewswire/ -- Data from two ongoing Phase II studies of Abbott Laboratories investigational protease inhibitor (PI), ABT-378/r ( lopinavir / ritonavir ), at 72 weeks continue to show suppression of HIV in both patients new to therapy and patients who have failed other therapies.
SAN DIEGO, July 11 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced the presentation of clinical data from HIV-infected patients being treated with the Company s investigational drug candidate HE2000 in a Phase I/II clinical trial in South Africa . The data were presented in a poster ses
DURBAN, South Africa , July 11 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported that, in a long-term study, a majority of people living with HIV who received VIRACEPT(R) (nelfinavir mesylate) combination therapy for three years in this clinical trial were shown to experience suppression of virus as well as
DURBAN, South Africa , July 11 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported results from studies evaluating safety and efficacy of RESCRIPTOR(R) ( delavirdine mesylate) Tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI), as part of combination therapy
DURBAN, South Africa , July 11 /PRNewswire/ -- The first AIDS vaccine candidate designed specifically for Africa will enter human trials this summer. The International AIDS Vaccine Initiative (IAVI) announced today that the Medicines Control Agency (MCA) of the United Kingdom has approved Phase I testing o
Preliminary Study Suggests: Plasma Levels of Amprenavir Are Raised By Low- Dose Ritonavir DURBAN, South Africa , July 11 /PRNewswire/ -- Preliminary results of a study of the protease inhibitor (PI)
DURBAN, South Africa , July 10 /PRNewswire/ -- In response to more than 40 percent of new HIV infections globally occurring in women, The Female Health Company (OTC Bulletin Board: FHCO), provider of The Female Condom(TM), is increasing efforts to help women in developing countries understand their role in prevention a
ABBOTT PARK, Ill., July 10 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) presented the first data in infants and children with the company s investigational protease inhibitor (PI), ABT-378/r ( lopinavir / ritonavir ) today at the 13th World AIDS Conference in Durban,
SEATTLE, and WHITEHOUSE STATION, N.J., July 10 /PRNewswire/ -- The Bill & Melinda Gates Foundation, Merck & Co. , Inc. (NYSE: MRK)(1) and the Republic of Botswana today announced the establishment of the Botswana Comprehensive HIV/AIDS Partnership , a new initiative to improve the overall state of HIV/AIDS care
DURBAN, South Africa , July 9 /PRNewswire/ -- The development pipeline for AIDS vaccines was virtually empty two years ago. Today, there are promising products in development but still no plan to get any useful vaccine to the most affected communities in the world. The International AIDS Vaccine Initiative (IAVI) today
EMERYVILLE, Calif., July 8 /PRNewswire/ -- Chiron (Nasdaq: CHIR) announced today that results from a Phase II study of Chiron s recombinant human interleukin-2 (rhIL-2, or aldesleukin) in patients with HIV infection show that patients receiving rhIL-2 in conjunction with standard antiretroviral therapy achieved signifi
EMERYVILLE, Calif., July 8 /PRNewswire/ -- Chiron (Nasdaq: CHIR) announced today that results from a Phase II study of Chiron s recombinant human interleukin-2 (rhIL-2, or aldesleukin) in patients with HIV infection show that patients receiving rhIL-2 in conjunction with standard antiretroviral therapy achieved signifi
DURBAN, SOUTH AFRICA, July 7 /PRNewswire/ -- The Female Health Company (Amex: FHCO) has teamed up with The Joint United Nations Programme on HIV/AIDS ( UNAIDS ) and the World Health Organization (WHO) to create a new educational guide about The Female Condom. The partners will launch the Guide at a satellite sympos
ST. PAUL, Minn., July 7 /PRNewswire/ -- Dr. Keith Henry, medical director of the HIV/AIDS Program at Regions Hospital, is one of 5,000 AIDS specialists including Nobel prizewinners, directors of leading research institutions, scientific academies and medical societies worldwide, to sign the Durban Declaration, a statem
DURBAN, South Africa , July 6 /PRNewswire/ -- Surgeon General David Satcher will host a July 9 press conference with leading Federal officials on the devastating impact of HIV/AIDS on the United States , especially among communities of color. The press conference, which will be a precursor to week long events during th
JOHANNESBURG, South Africa , July 6 /PRNewswire/ -- Five countries in the sub-Saharan region are to receive seventeen Secure the Future grants more than US$7.5 million (R45 million), to support medical research and community outreach and education projects aimed at combating HIV/AIDS. This brings the total Secure the F
PITTSBURGH, July 6 /PRNewswire/ -- A computerized medication monitoring system has shown that HIV patients must be at least 95 percent adherent to antiretroviral therapy for the drugs to work, report investigators from the University of Pittsburgh Medical Center (UPMC). In a startling twist, the study also reveals that
PITTSBURGH, July 6 /PRNewswire/ -- A computerized medication monitoring system has shown that HIV patients must be at least 95 percent adherent to antiretroviral therapy for the drugs to work, report investigators from the University of Pittsburgh Medical Center (UPMC). In a startling twist, the study also reveals that
DEERFIELD, Ill., and FOSTER CITY, Calif., July 5 /PRNewswire/ -- Fujisawa Healthcare, Inc. and Gilead Sciences , Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration ( FDA ) approved the antifungal drug AmBisome(R) ( (amphotericin B) liposome for injection) for the treatment of cryptococcal meningit
NEW YORK, July 5 /PRNewswire/ -- AIDS Treatment activists from around the world will be rallying for acceleration of HIV vaccine research at the 13th World AIDS Conference in Durban, South Africa to begin July 19, 2000. The successful development of an HIV vaccine is the only answer for the future of 70 million people
BERKELEY, Calif., July 3 /PRNewswire/ -- Genome scientist Dr. Howard Urnovitz offered his insight into the role of HIV in AIDS for the upcoming Durban 13th International AIDS Conference. One topic the conference will be addressing is the decade old debate of what role the virus HIV plays in AIDS. Dr. Urnovitz s researc
MELBOURNE, Australia , June 27 /PRNewswire/ -- Virax Holdings Limited (ASX: VHL) and Institute of Drug Technology Australia Limited (ASX: IDT) today announced that, the Australian consortium, of which they are a member, is to receive $27 million (US$16) from the US National Institutes of Health (NIH) to fast track the
BETHESDA, Md., June 27 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID) announced today four novel public-private partnerships to accelerate development of promising HIV/AIDS vaccines for use around the world. The new partnerships, called HIV Vaccine Design and Development Teams (HVDDT)
EMERYVILLE, Calif., June 27 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) announced today that the company has been awarded a five year contract from the National Institutes of Health (NIH) to advance its HIV vaccine program into human clinical trials. The total value of the contract to Chiron will be approximately
PHILADELPHIA, June 27 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said that the recent Executive Order by President Clinton to increase benefits of Medicare Beneficiaries in Clinical Trials should significantly accelerate enrollment in, and expansion of, its major U.S.-based clinical trials in both AI
WASHINGTON, June 26 /PRNewswire/ -- Surgeon General David Satcher today said more Americans should take control of their health by getting tested for the HIV virus. An estimated 250,000 people in the United States are unaware that they are infected with HIV, the virus that causes AIDS, Satcher said. Testing is a crit
DURBAN, South Africa , June 26 /PRNewswire/ -- People with HIV disease and healthcare professionals from around the world will be able to view sessions from the XIII International AIDS Conference on the World Wide Web, according to organizers of this global meeting. The Webcast (webcast.aids2000.com) will feature scien
NEW YORK, June 23 /PRNewswire/ -- Immediately following a legislative forum attended by Congressmen Ed Towns, Major Owens and Nydia Valasquez with people living with AIDS in Brooklyn on Monday, AIDS activists began to rally for the immediate FDA approval of the first reliable rapid oral fluid test OraQuick, for HIV man
NEW YORK, June 22 /PRNewswire/ -- In a surprising announcement by William Carter, MD, CEO of Hemispherix Biopharma, it was made known today that Hemispherix Biopharma will be retaining Anderson Clinical Research to conduct clinical trials on Ampligen for the treatment of drug resistant HIV. For the past year, at the re
PHILADELPHIA, June 22 /PRNewswire/ -- Biosyn, Inc. announced today that a Phase I clinical trial for SAVVY vaginal microbicide, currently under development, has concluded with results indicating that SAVVY may be a safe and effective method of contraception. This study, conducted at the University of Pennsylvania Medic
PHILADELPHIA, June 21 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC) today announced that it has been selected as a National AmeriCorps site. Luciano Orsini, President of the Consortium s Board of Directors said, We are thrilled to have been chosen in this highly competitive, national process to serve as a dir
WASHINGTON, June 21 /PRNewswire/ -- To help identify nearly 250,000 people in the United States who do not know they are infected with HIV, the virus that causes AIDS, the National Association of People with AIDS (NAPWA) announced today the sixth annual National HIV Testing Day, June 27. NAPWA is urging Americans at ri
CARLSBAD, Calif., June 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today preliminary interim clinical results which indicate REMUNE(TM) (HIV-1 Immunogen) may stimulate cytotoxic T lymphocytes (CTL) or killer T cell activity specifically against HIV, the AIDS virus, in people infected wit
PHILADELPHIA, June 26 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said it has just received FDA authorization to conduct a major Phase 2/3 clinical study in HIV disease resistant to all presently available therapies. The clinical study will involve 100 patients residing in the continental
LOS ANGELES, June 19 /PRNewswire/ -- In the spirit of Day of Compassion and through the shared vision of AIDS Project Los Angeles (APLA) and HonorALife.com ( http://www.honoralife.com ), the AIDS Commemorative serves as a virtual AIDS memorial -- a place to honor, observe, and remember those who have moved us, and insp
NEW YORK, June 15 /PRNewswire/ -- The following statement is being issued by Beny Primm, M.D.: I recently facilitated a summit to develop new and effective ways to combat the HIV/AIDS epidemic in the African-American community here in the United States . This historical meeting, organized by pharmaceutical leader
SITGES, Spain , June 14 /PRNewswire/ -- Data presented today at the 4th International Workshop on HIV Drug Resistance & Treatment Strategies demonstrate that HIV patients whose physicians used the results of Antivirogram(TM), Virco s phenotypic HIV resistance test, to guide their choice of therapy, received more ac
SITGES, Spain , June 14 /PRNewswire/ -- Data presented today at the 4th International Workshop on HIV Drug Resistance & Treatment Strategies demonstrate that HIV patients whose physicians used the results of Antivirogram(TM), Virco s phenotypic HIV resistance test, to guide their choice of therapy, received more ac
TORONTO, June 14 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq: VGIN) reported that preliminary six-month data presented today in Sitges, Spain at the 4th International Workshop on HIV Drug Resistance and Treatment Strategies from the NARVAL study showed a benefit to HIV-infected patients who received HIV drug resistan
SITGES, Spain , June 13 /PRNewswire/ -- Data presented by Virco at the 4th International Workshop on HIV Drug Resistance & Treatment Strategies demonstrates that 27.2% of 11,990 HIV patients being surveyed had HIV that was resistant to all three classes of HIV drugs currently available. The U.S. survey conducted i
SITGES, Spain , June 12 /PRNewswire/ -- A number of important studies to be presented here this week at the 4th International Workshop on HIV Drug Resistance and Treatment Strategies demonstrate the superior accuracy and sensitivity of PhenoSense HIV, a phenotypic HIV drug resistance test developed and marketed by Viro
DURHAM, N.C., June 12 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that it will present data on the antiviral activity of DAPD in HIV-infected patients who have failed multiple antiviral drugs. The data are being presented at the 4th International Workshop on HIV Drug Resistance and Tre
DURHAM, N.C., June 12 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that it will present the initial results of a Phase I/II dose escalation combination study conducted outside the U.S. of DMP-450, a protease inhibitor for the treatment of HIV infection that belongs to a novel chemical c
NEW YORK, June 9 /PRNewswire/ -- The National Association of People With AIDS (NAPWA) is sponsoring the 6th Annual National HIV Testing Day on Tuesday, June 27, to improve the health of people living with HIV, promote HIV testing, and encourage people to learn their HIV status and take control of their health and lives
CARLSBAD, Calif. and LA JOLLA, Calif., June 9 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) and Agouron Pharmaceuticals, Inc. today announced that they have been informed by the AIDS Clinical Trials Group (ACTG) that enrollment in the 96 week, randomized, double-blind, adjuvant- controlled study, previ
VIENNA, Va., June 6 /PRNewswire/ -- CEL-SCI Corporation (Amex: CVM; Frankfurt/Berlin: LSR) announces that all six samples of blood sera tested from HIV-1 subtype C infected patients living in South Africa recognized the HGP-30W AIDS vaccine sequence. CEL-SCI believes that these results support further clinical evaluati
WASHINGTON, June 6 /PRNewswire/ -- The Medical University of Southern Africa (MEDUNSA) honors Bristol-Myers Squibb s Chairman and Chief Executive Officer Charles A. Heimbold Jr. today with The Nelson Mandela Award for Outstanding Leadership to recognize his efforts in establishing Secure the Future, which provides care
MARNES-LA-COQUETTE, France , June 5 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (Amex: BIO.A and BIO.B) announces the introduction of its new Genscreen Plus(TM) HIV Ag/Ab reagent kit, used to assess a patient s exposure to the virus that causes AIDS. The advantage of this assay is its ability to detect an extremely low
NEW YORK, June 5 /PRNewswire/ -- A new clinical study has found that the leading hepatitis C treatment is effective in patients co-infected with HIV, does not interfere with HIV medications, and may even make it possible for more HIV patients to be treated, according to researchers. In the past, physicians didn t treat
LOS ANGELES, June 1 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation and Ty, Inc. today announced the newest Beanie Baby created in memory of Elizabeth and Paul Glaser s daughter, Ariel who died in 1988 from complications from AIDS. All profits of Ty, Inc. from its sale will be donated to the Foundation.
ACCRA, Ghana , June 1 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) announced the launch of the female condom in Ghana on May 25, 2000. Her Excellency Nana Konadu Agyeman Rawlings, the First Lady of Ghana presided over the official launch stating The female condom is a long awaited global dream c
ABBOTT PARK, Ill., June 1 /PRNewswire/ -- Abbott Laboratories announced today that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration ( FDA ) to market ABT-378/r, also known as lopinavir / ritonavir , i
TARRYTOWN, N.Y., May 30 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported today the discovery of the binding site for HIV on CCR5, a receptor protein found on cells that plays a critical role in HIV entry and infection. The new structural data provide researchers with a better understanding of how
WASHINGTON, May 22 /PRNewswire/ -- The Chairman of the Corporate Council on Africa, Maurice Tempelsman, announced today the formation of a Corporate Task Force on AIDS in Africa. The role of the task force will be to examine what American corporations operating in Africa can do to better support the fight against AIDS
BALTIMORE, May 22 /PRNewswire/ -- VirtualPhenotype(TM), a powerful new quantitative approach to HIV resistance testing, is now available in the U.S. via Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), Virco announced today. The greatly enhanced system, developed by Virco, uses the company s propr
SHORT HILLS, N.J., May 22 /PRNewswire/ -- Insufficient funding and the stigma of having HIV/AIDS are the two biggest reasons the disease is spreading at epidemic proportions in African-American communities, according to more than 50 political, social and community activists who participated in a weekend summit in Short
NEW YORK, May 11 /PRNewswire/ -- The International AIDS Vaccine Initiative said it welcomed the announcement of a new dialogue between the United Nations and the pharmaceutical industry aimed at providing AIDS drugs at a deep discount for people living in poor countries. It has long been evident that new types of publi
BALTIMORE, May 19 /PRNewswire/ -- The development of an innovative, orally administered AIDS vaccine by the Institute of Human Virology (IHV) will be funded by the International AIDS Vaccine Initiative (IAVI) under terms of a new multi-year, multi-million dollar vaccine development partnership agreement between the org
EMERYVILLE, Calif., May 19 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) announced today that a federal district court in Dusseldorf, Germany issued a judgment finding that certain HIV polynucleotides used in F. Hoffman-LaRoche s HIV PCR diagnostic tests infringe Chiron s European Patent No. 0 181 150, including it
WASHINGTON, May 18 /PRNewswire/ -- The AIDS Vaccine Advocacy Coalition (AVAC) today challenged Presidential candidates George W. Bush and Al Gore to outline a comprehensive plan to accelerate AIDS vaccine development and to endorse legislation now pending in Congress that would provide incentives for vaccine research.
NEW YORK, May 18 /PRNewswire/ -- Governor George W. Bush has made his first comments regarding HIV/AIDS issues, to be released today exclusively in the HIV medical journal and Internet guide, Numedx. Bush s response to AIDS, as well as Vice President Gore s, is presented in a Question & Answer debate format. Issues
CHICAGO, May 18 /PRNewswire/ -- An unprecedented cross-section of Chicago s religious leaders will gather today at an interfaith breakfast meeting to learn first-hand about the pediatric AIDS crisis in sub-Saharan Africa and how their congregations may help children living with HIV/AIDS through a new international prog
PHILADELPHIA, May 17 /PRNewswire/ -- Biosyn, Inc. announced today that an investigational study of ORAMED, an oral rinse treatment for oral candidiasis, showed positive results in a population of HIV / AIDS patients. The final results of the randomized, placebo-controlled, Phase I/II study showed that ORAMED was safe a
TARRYTOWN, N.Y., May 17 /PRNewswire/ -- Bayer Diagnostics announced today that it has completed its Premarket Approval Application (PMA) to the U.S. Food and Drug Administration ( FDA ) for approval of its viral load test for HIV -- the Bayer HIV-1 RNA 3.0 Assay (bDNA). This test utilizes proprietary branched DNA techn
CHICAGO, May 16 /PRNewswire/ -- In a major step to provide HIV/AIDS- treating physicians in five southern Africa nations with access to Internet- based health information and cutting-edge distance learning capabilities, the International Association of Physicians in AIDS Care (IAPAC) is launching I- Med Exchange -- a b
SAN FRANCISCO, May 11 /PRNewswire/ -- Better World Advertising (BWA) is holding auditions for HIV positive Gay / Bisexual men and Transgenders from the Bay Area to appear in a ground-breaking new HIV STOPS WITH ME television commercial to be aired in the Fall of 2000. The commercial will be aired during primetime based
BALTIMORE, May 11 /PRNewswire/ -- In response to recent guidelines, issued by an independent international panel of expert HIV/AIDS physicians and scientists recommending the use of HIV drug resistance testing to guide treatment decision-making as part of routine clinical practice, Virco is providing an update on avail
WHITEHOUSE STATION, N.J., May 11 /PRNewswire/ -- Merck & Co. , Inc.(1) (NYSE: MRK) has joined with leading international health and development agencies and four other pharmaceutical companies to form an important new public/private sector cooperation to accelerate access to HIV/AIDS care and treatment in developin
FERNDALE, Mich., May 10 /PRNewswire/ -- The Hemophilia Foundation of Greater Florida (HFGF) will host the state s first exhibit of STITCHES: A Doll Project, a new program that uses dolls designed by HIV-positive women to help promote public awareness about AIDS, and to ensure that the life experiences of HIV-positive w
MIAMI LAKES, Fla., May 10 /PRNewswire/ -- World Diagnostics, Inc. (OTC Bulletin Board: WDGI), a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products, announced today, that CAREC will use WDI s online GLOBALeMED system for technical training and information concerning Infectio
CARLSBAD, Calif., and LA JOLLA, Calif., May 10 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) and Agouron Pharmaceuticals, Inc. today announced that a pivotal trial has been initiated to evaluate the safety and efficacy of the investigational product REMUNE(TM) (HIV-1 Immunogen) in increasing durability
SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire/ -- Guidelines published today in the Journal of the American Medical Association (JAMA) recommend the use of drug resistance testing in the clinical management of HIV patients in several settings. The guidelines were developed by an international panel of 13 physician ex
WASHINGTON, May 9 /PRNewswire/ -- The confluence of HIV/AIDS, drug abuse, and hepatitis C is becoming a public health nightmare. HIV/AIDS and hepatitis C are moving at an alarming rate into the minority community, where the poorest and most vulnerable are at risk through injection drug use and unprotected sex. To count
WATERTOWN, Mass., May 3 /PRNewswire/ -- V.I. Technologies, Inc. (VITEX) (Nasdaq: VITX) announced today that the Health Care Financing Administration (HCFA) of the U.S. Department of Health and Human Services has assigned a product code -- P9023 -- and reimbursement rate for PLAS+(R)SD, the Company s transfusion plasma
BRISBANE, Calif., May 3 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) announced today that its AIDS vaccine trials received their third, consecutive positive review from the independent Data and Safety Monitoring Board (DSMB) overseeing the trials. Additionally, VaxGen noted that 96 percent of the trial volunteers conti
MIAMI LAKES, Fla., May 2 /PRNewswire/ -- World Diagnostics, Inc. (OTC Bulletin Board: WDGI), a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products, announced today, that its Argentine distributor, Branstar Corporation SA has completed registration with the government of
OXFORD, England and MADISON, Wis., May 2 /PRNewswire/ -- PowderJect Pharmaceuticals Plc (LSE: PJP) and its wholly owned subsidiary, PowderJect Vaccines Inc., today announced results from two studies demonstrating important advances in the development of a DNA vaccine to combat HIV. The studies, carried out in a widely
SAINT PAUL, Minn., May 2 /PRNewswire/ -- Formally designated as a threat to U.S. national security, AIDS is expected to rise for a decade before there is much prospect of improvement. It is known that the main reason available drug treatments fail in AIDS patients is the emergence of multidrug resistance. Therefore, ne
Substance abuse is a doorway to HIV/AIDS infections, hepatitis C and other diseases. Injection drug use and unprotected sex are key public health factors in the spread of HIV/AIDS. HIV/AIDS is moving rapidly into the minority community, where the poorest and most vulnerable are at risk. Substance abuse treatment must b
WASHINGTON, May 1 /PRNewswire/ -- The Clinton Administration is pushing for increased distribution of condoms as the ultimate solution to the AIDS pandemic in sub-Saharan Africa, said Mark DeYoung of American Life League, yet we have no reason to believe that increased access to condoms will decrease the spread of AIDS
VIENNA, Va., May 1 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM, Berlin/Frankfurt Stock Exchanges: LSR) announced today that it has offered the South African government a free license to test and use the Company s AIDS vaccine in South Africa. In exchange for this license, CEL-SCI requested that the South African gov
ALEXANDRIA, Va., May 1 /PRNewswire/ -- America s needy seniors lacking prescription drug coverage and their families are bearing an intolerable burden, and should not have to wait years for a new President and new Congress to find a solution, according to Craig F. Fuller, President and CEO of the National Association o
NEW YORK, April 24 /PRNewswire/ -- Depression tops the list of health concerns for lesbian and gay men, according to an exclusive gay health survey just released by GayHealth.com(TM) (http://www.gayhealth.com). The site, which launched April 15th, is the first worldwide source of health and wellness information for the
PHILADELPHIA, April 18 /PRNewswire/ -- Adolescents infected with the virus that causes AIDS have a surprisingly robust immune response and may benefit particularly well from aggressive early treatment with anti-HIV medications, according to a research team led by an immunologist at The Children s Hospital of Philadelph
BALTIMORE, April 17 /PRNewswire/ -- Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) said that new ex vivo tests, reported today at the 13th International Virology Conference, may provide new insights into possible treatment of the newly emerging types of HIV virus which mutate into drug- resistant forms. The tests, perfo
FOSTER CITY, Calif., April 17 /PRNewswire/ -- Gilead Sciences , Inc. (Nasdaq: GILD) today announced preliminary results from a Phase II dose-ranging clinical trial (Study 902) evaluating the safety and efficacy of once-daily tenofovir disoproxil fumarate (tenofovir DF) when used to intensify a stable background antiret
CHICAGO, April 14 /PRNewswire/ -- Results of a new study presented today at the 3rd International Workshop on Salvage Therapy for HIV Infection indicate that the use of a test for HIV drug resistance can significantly reduce the cost of care in addition to improving patients response to treatment. The randomized contro
CHICAGO, April 13 /PRNewswire/ -- Results from two retrospective studies showed that Crixivan (R) ( indinavir sulfate) combined with low dose ritonavir(A) twice-daily suppressed HIV in many patients who were no longer responding to protease-inhibitor containing therapy, including treatment with
CARLSBAD, Calif., April 13 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that Remune(TM) (HIV-1 immunogen), its potential immune-based therapy for the treatment of HIV infection, appears to boost CD4 helper T-cell (immune cell) activity against HIV in chronically (long-term) infected pa
PHILADELPHIA, April 12 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said that it would be providing Ampligen to certain HIV treatment specialists in the USA for FDA authorized emergency treatment of individuals with AIDS who are developing resistance to currently approved regimens. We are very exc
NEW YORK, April 10 /PRNewswire/ -- Seth Berkley, M.D., president of the International AIDS Vaccine Initiative (IAVI), issued the following statement about the XIII International AIDS Conference (AIDS 2000), to be held in Durban, South Africa July 9-14, 2000. AIDS 2000 is the first international AIDS conference to be he
PLANTATION, Fla., April 10 /PRNewswire/ -- PhyloMed Corporation, a biopharmaceutical company located in Plantation, Florida, has developed and patented a series of modified peptides (small proteins) which show promise in the treatment of AIDS, Multiple Sclerosis, Viral Disease and Cancer. The Company has pioneered new
SAN DIEGO, April 10 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced presentation of preliminary clinical data from its first two cohorts of HIV patients treated with 50 mg and 100 mg doses of HE2000 in a South African Phase I/II clinical trial. The data was presented in a poster session
DURHAM, N.C., April 7 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS - news) announced that following discussions yesterday and this morning with the U.S. Food and Drug Administration ( FDA ), the FDA has issued a clinical hold on study FTC-302 which is being conducted under a U.S. IND in
DURHAM, N.C., April 6 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) at 8:30 this morning received a letter from the Medicines Control Council (MCC) in South Africa . The letter informed Triangle that Study FTC-302 should be terminated. The Company is in ongoing discussions with the MCC. The Company rec
DURHAM, N.C., April 6 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today clarified an inconsistency in a report that appeared in the popular media in South Africa yesterday. In one part of the report, it was suggested that a clinical trial being sponsored by Triangle has been halted. A quote in the re
KEYSTONE, Colo., April 6 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented promising findings on two treatment strategies designed to prevent HIV from infecting healthy cells and to eliminate those cells already infected with virus. The results were described in separate presentations at th
COLUMBUS, Ohio, April 5 /PRNewswire/ -- Drug Emporium, Inc., a leading discount drugstore chain (Nasdaq: DEMP), and its subsidiary, DrugEmporium.com, a leading online drugstore, announced today that customers needing to refill a prescription from their local Drug Emporium store can now choose to place the order online
DURHAM, N.C. and BERKLEY, Calif., April 4 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) and Dynavax Technologies Corporation have entered into a collaborative agreement to develop immunostimulatory pharmaceutical candidates intended to be used to modulate the human immune response for the treatment and
AUSTIN, Texas, March 24 /PRNewswire/ -- Teenage pregnancy and sexually transmitted diseases are at epidemic proportions. According to the Robin Hood Foundation report Kids Having Kids, in 1997, 12.7 percent of all babies born in the U.S. were by teenage mothers. Teenagers account for 25 percent of sexually transmitted
WESTON, Mass., March 31 /PRNewswire/ -- Health care workers suffer over half a million needlestick injuries each year in the US. Infection from a contaminated needlestick may lead to HIV, hepatitis-B, and hepatitis-C disease. Who pays the cost of treating these infected nurses, aides, and physicians, which can run as h
COLUMBUS, Ohio and DEERFIELD, Ill., March 30 /PRNewswire/ -- Roxane Laboratories , Inc. and Unimed Pharmaceuticals, Inc. today announced that California state authorities have rescheduled MARINOL(R) (dronabinol) from a Schedule II to a Schedule III drug, thus easing the prescribing restrictions imposed on physicians ch
COLUMBUS, Ohio and DEERFIELD, Ill., March 30 /PRNewswire/ -- Roxane Laboratories , Inc. and Unimed Pharmaceuticals, Inc. today announced that California state authorities have rescheduled MARINOL(R) (dronabinol) from a Schedule II to a Schedule III drug, thus easing the prescribing restrictions imposed on physicians ch
CARLSBAD, Calif., March 29 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today data from preclinical animal studies of a potential new vaccine consisting of the Company s HIV immunogen, Remune(TM) (whole-killed HIV depleted of gp120 coat proteins in Incomplete Freund s Adjuvant) combined with
CARLSBAD, Calif., March 29 /PRNewswire/ -- iMetrikus, an e-health company providing personalized interactive health management services for people living with chronic illnesses, has partnered with AEGiS, the world s largest and most popular HIV/AIDS information Web site. The multi-year partnership with AEGiS underscore
PHILADELPHIA, March 17 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB) today said that new data will be presented on anti-HIV studies by Dr. William E. Robinson, Jr., an associate professor at the University of California at Irvine at the 13th International Conference on Antiviral Research on April 16-21, 2000,
PITTSBURGH, March 28 /PRNewswire/ -- A new understanding about HIV transmission in women -- information that could lead to preventative strategies for this population -- will likely come from an organ culture model recently developed by researchers at the University of Pittsburgh s Graduate School of Public Health (GSP
MEDFORD, Mass., March 27 /PRNewswire/ -- Privately held Consensus Pharmaceuticals, Inc. announced today the award of a USD $99,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health in Bethesda, MD. The
NEW YORK, March 24 /PRNewswire/ -- NIAC/AWF AIDS CONFERENCE, - Cambridge Nutraceuticals announced today that the New York Medicaid system has approved coverage of its glutamine-based Immune System Booster for patients with HIV/AIDS. The Immune System Booster helps maintain weight and body cell mass which have been link
BURLINGTON, N.C., March 23 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced the signing of an agreement to provide ViroLogic Inc. s phenotypic HIV drug susceptibility assay, PhenoSense(TM) HIV, through LabCorp s national laboratory services network. This agreement ad
CARLSBAD, Calif., March 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that recent clinical data suggest that REMUNE(TM), its immune-based therapy to treat HIV infection, may induce HIV immunity when used as a combination therapy with other antiviral drugs or when used alone as a mono
WASHINGTON, March 23 /PRNewswire/ -- In a soon-to-be released review of federal AIDS funding, the General Accounting Office (GAO) reports that Ryan White CARE Act funding substantially underfunds the African American and Hispanic communities. The GAO finds that: * Compared with whites, African Americans, Hispanics, and
BURLINGTON, N.C., March 23 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced the signing of an agreement to provide ViroLogic Inc. s phenotypic HIV drug susceptibility assay, PhenoSense(TM) HIV, through LabCorp s national laboratory services network. This agreement ad
CARLSBAD, Calif., March 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that recent clinical data suggest that REMUNE(TM), its immune-based therapy to treat HIV infection, may induce HIV immunity when used as a combination therapy with other antiviral drugs or when used alone as a mono
WILMINGTON, Del., March 20 /PRNewswire/ -- As evidence of a shifting trend away from the widespread use of protease inhibitors , more prescriptions were written for DuPont Pharmaceuticals Sustiva (TM) ( efavirenz ), a non-nucleoside reverse tra
WILMINGTON, Del., March 20 /PRNewswire/ -- As evidence of a shifting trend away from the widespread use of protease inhibitors , more prescriptions were written for DuPont Pharmaceuticals Sustiva (TM) ( efavirenz ), a non-nucleoside reverse tra
NEW YORK, March 17 /PRNewswire/ -- The following is being issued by Asensio & Company, a member of the National Association of Securities Dealers, CRD number 31742: Hemispherx Biopharma, Inc. (Amex: HEB) announced in press releases on December 16, 1999 and February 22, 2000 that it presented HIV test findings at a
PRINCETON, N.J., March 16 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration ( FDA ) granted a priority review for VIDEX(R) capsules, also known as ddI. If approved, the new VIDEX drug product will be the first and only, one capsule, once-daily HIV drug a
PRINCETON, N.J., March 16 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration ( FDA ) granted a priority review for VIDEX(R) capsules, also known as ddI. If approved, the new VIDEX drug product will be the first and only, one capsule, once-daily HIV drug a
TARRYTOWN, N.Y., and PRINCETON, N.J., March 15 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Pharmacopeia, Inc. (Nasdaq: PCOP) have announced the signing of a new collaborative agreement to discover small-molecule HIV therapeutics, significantly broadening the scope of their previous program. The p
SAN DIEGO, March 15 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company a patent relating to the Company s core vaccine technology. The patent is U.S. Patent Number 6,037,135 entitled Methods of Making HLA Binding Peptides and Their Uses,
TAORMINA, Italy (ots-PRNewswire) - More than 750 European physicians convened here to discuss results of important clinical trials confirming the efficacy of the anti-HIV drug VIRAMUNE(R) ( nevirapine ) for the treatment of HIV-infected patients. Studies relating to adult and paediatric HIV treatment, as well as ground
SAN FRANCISCO, March 13 /PRNewswire/ -- Women are the fastest growing population at risk for HIV, the virus that causes AIDS, in the United States . Approximately 22 percent of the HIV-infected population in this country are women, and women of color are disproportionately affected -- 80 percent are African-American or
SEATTLE, March 9 /PRNewswire/ -- Researchers at the Fred Hutchinson Cancer Research Center and the University of Washington have discovered a mechanism that may open a new window of understanding into the process of how retroviruses such as HIV infect cells. A report of this discovery, by senior author Julie Overbaugh,
LOS ANGELES, March 9 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announced today grants totaling $800,000 to provide necessary resources to begin implementation of programs for reducing the transmission of HIV from mother to infant in developing countries. The Board of Directors of the Elizabeth Glas
LOS ANGELES, March 8 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announced today the creation of the Glaser Pediatric Research Network, an innovative and collaborative partnership, linking world-class scientific centers to accelerate progress on serious and life-threatening pediatric illnesses. A pri
FOSTER CITY, Calif., and BALTIMORE, March 7 /PRNewswire/ -- Gilead Sciences , Inc. (Nasdaq: GILD) and Virco today announced a collaboration to promote Virco s HIV resistance monitoring tests and services (Antivirogram(TM), VircoGEN(TM) and VirtualPhenotype(TM)) designed to characterize the susceptibility to available d
BUFFALO GROVE, Ill., March 7 /PRNewswire/ -- Curatek Pharmaceuticals today announced that it has begun Phase III human clinical trials with topical clonidine gel, an innovative treatment for peripheral neuropathic pain, including widespread and frequently debilitating conditions where current treatments are often ineff
SOUTH SAN FRANCISCO, Calif., March 7 /PRNewswire/ -- At the 4th International Conference on New Trends in Clinical and Experimental Immunosuppression held February 17-20, 2000 in Geneva, Switzerland , scientists presented results of in vitro and in vivo studies to identify genes acutely responsive to WF10, a macrophage
BRISBANE, Calif., March 7 /PRNewswire/ -- VaxGen Inc. (Nasdaq: VXGN), the leading developer of preventive HIV/AIDS vaccines, today joined the commitment made last week by the public and private sectors to speed the development and distribution of vaccines to the developing world. At a meeting called by President Clin
WASHINGTON, March 6 /PRNewswire/ -- Last week, the Senate Health, Education, Labor and Pension Committee held a hearing to review the reauthorization of the Ryan White CARE Act. The original bill appropriates money based on AIDS-related data. Because AIDS is the last stage of HIV infection, funding is based on the HIV
LA JOLLA, Calif., March 6 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today announced that the Food and Drug Administration ( FDA ) has approved a film-coated version of VIRACEPT(R) (nelfinavir mesylate) Tablets. This new formulation is part of Agouron s continuous efforts to meet the needs of patients with HIV infec
CARLSBAD, Calif., March 6 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today the presentation of new data appearing to demonstrate that people infected with HIV-1 who are treated with REMUNE(TM) (an immune-based therapy consisting of whole inactivated HIV-1 virus depleted of its gp120 coat p
MARNES-LA-COQUETTE, France , March 3 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (Amex: BIO.A, BIO.B) announced today that a patent infringement lawsuit concerning production of a diagnostic test for HIV-2 was decided in its favor. On February 4, 2000, Singapore Judicial Commissioner Tay Yong Kwang found that Si
NEW YORK, March 3 /PRNewswire/ -- Researchers announced today that there has been a sharp drop in the rate of new HIV infections among injecting drug users in New York City. During the 1980s, the rate of new infections was 4 percent to 5 percent per year among drug injectors in New York who were not already infected wi
SAN FRANCISCO, March 3 /PRNewswire/ -- More than 1,800 researchers, policy makers, educators, and people living with HIV and AIDS will convene in San Francisco. March 15-17, for the 12th annual National HIV/AIDS Update Conference (NAUC). Presented annually in San Francisco, NAUC is the longest running HIV/AIDS conferen
TAOS, N.M., March 2 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) reported today new discoveries on the structure and function of CCR5, a human receptor protein that plays a critical role in HIV fusion and infection. Presented at the Keystone Symposium on Cell Biology of Virus Entry, Replication
WASHINGTON, March 2 /PRNewswire/ -- The International AIDS Vaccine Initiative, a public-private partnership funded by governments, foundations and multilateral organizations, announced on Thursday that it will triple, to six, the number of different AIDS vaccine candidates for developing countries that it is sponsoring
ROCKVILLE, Md., March 2 /PRNewswire/ -- People who are diagnosed with AIDS/HIV face unique financial challenges, said Debt Counselors of America President Steve Rhode. An AIDS/HIV diagnosis drastically changes a person s life. One of the many worries that result from the diagnosis is what to do about money. Rhode says
SAN FRANCISCO, Feb. 28 /PRNewswire/ -- The 12th annual National HIV/AIDS Update Conference (NAUC), which showcases the latest in HIV/AIDS research, prevention, public policy, and care, will be held March 14-17 in SanFrancisco. Organized by the American Foundation for AIDS Research (amfAR), NAUC will feature Sandra Thur
WASHINGTON, Feb. 24 /PRNewswire/ -- Rev. Jesse L. Jackson, Sr., president and founder of the Rainbow/PUSH Coalition, surrounded by other prominent leaders, called for more grassroots initiatives and government action to address the HIV/AIDS epidemic within the African-American community. This announcement was made earl
SAN DIEGO, Feb. 29 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) today announced the identification of a novel vaccine candidate for the prevention and treatment of hepatitis C at the Keystone Symposia scientific meetings in Santa Fe, New Mexico. The Company has pioneered a new approach to vaccine development using epit
NEW YORK, Feb. 28 /PRNewswire/ -- Seth Berkley, M.D., president of the International AIDS Vaccine Initiative (IAVI), issued the following statement after UNAIDS released a new set of international ethical guidelines on AIDS vaccine research: An affordable AIDS vaccines is the world s only hope for ending this terrible
HERCULES, Calif., Feb. 25 /PRNewswire/ -- Bio-Rad Laboratories, Inc., (Amex: BIO.A and BIO.B) announced that the FDA ( United States Food and Drug Administration) has approved two of its licensed assays for use with cadaveric serum samples. The need for cadaveric HIV and Hepatitis testing is largely focused on the requ
WASHINGTON, Feb. 24 /PRNewswire/ -- Rev. Jesse L. Jackson, Sr., president and founder of the Rainbow/PUSH Coalition will give opening remarks today at the 2000 National Conference on African-Americans and AIDS. The Conference is a forum that brings together public health officials, medical and AIDS service organization
CARLSBAD, Calif., Feb. 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the results from a double blind placebo controlled trial of REMUNE(TM) alone versus adjuvant alone in 297 Thai HIV-1 infected subjects were presented to the World Health Organization (WHO) and the Joint Uni
African-Americans can be hesitant when it comes to getting tested for HIV/AIDS. According to a recent survey of African-Americans, 94% would agree to be tested if they were assured that their results would be kept confidential. Programs that erase the fear and stigma associated with the testing process must be implemen
NEW YORK, Feb. 21 /PRNewswire/ -- Infinity Info Systems Corp., a full-service computer consulting organization, today announced that SalesLogix Corporation (Nasdaq: SLGX), a leading provider of customer relationship management (CRM) and e-commerce software, has donated SalesLogix products to the International AIDS Vacc
The 2000 National Conference on African-Americans and AIDS is an annual forum to focus on HIV/AIDS in the African-American community. What: Leading AIDS experts from medical, research, government, public health, religious and corrections backgrounds will address a wide range of issues relating to African-Americans and
PHILADELPHIA, Feb. 17 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today announced that it has filed for HIV Emergency Treatment IND and Phase II and Phase III trials with the Food and Drug Administration. The Company s new HIV Emergency Treatment IND application is intended to be used to study the eff
PRINCETON, N.J., Feb. 17 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO) today announced that the Ministry of Health in Lebanon has approved ABELCET(R) (Amphotericin B Lipid Complex Injection) for the treatment of invasive fungal infections in patients who are refractory to or intolera
CARLSBAD, Calif., Feb. 17 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that their scientists have synthesized a proprietary new human Factor VIII gene, which may lead to improvements in the development of gene therapy for people with hemophilia A. In animal studies, the Company has sho
ROCKVILLE, Md., Feb. 16 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that it was issued a U.S. patent on a human gene that produces what is believed to be the critical entry point for the AIDS virus. The gene, known as the CCR5 receptor gene, gives rise in human cells to a protein that fun
BOULDER, Colo., Feb. 16 /PRNewswire/ -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) announced today the initiation of a Phase I clinical trial with the first dose of an anti-Hepatitis C virus ribozyme therapy given to a human volunteer. The first study of the anti-Hepatitis C virus ribozyme, LY466700 will consi
NEW YORK, Feb. 16 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI), Targeted Genetics Corporation (Nasdaq: TGEN), and Children s Research Institute on the campus of Children s Hospital in Columbus, Ohio (Children s), today announced that they will collaborate to develop a vaccine to prevent AIDS. The va
GABORONE, Botswana , Feb. 15 /PRNewswire/ -- The first laboratory and training center in Botswana devoted exclusively to the advanced study of HIV opened today in Gaborone. The facility will allow researchers in this southern African nation to conduct the first major study of HIV -1C subtype. The study aims to identify
SWAZILAND, Feb. 15 /PRNewswire/ -- A unique collaborative partnership has been formed to help alter the course of HIV/AIDS in Swaziland it was announced here today. Led by Bristol-Myers Squibb s Secure The Future initiative, the coalition includes the Missionary Sisters of the Sacred Heart, the Faculty of Health Scienc
CARLSBAD, Calif., Feb. 14 /PRNewswire/ -- Scientists at Isis Pharmaceuticals (Nasdaq: ISIP) published results from studies showing that Isis proprietary second-generation 2 -methoxyethyl chemistry provides significant improvement in safety compared to first-generation antisense drugs in animal studies. The paper is
SAN FRANCISCO, Feb. 14 /PRNewswire/ -- Aggressive AIDS Prevention, Inc., with the corporate sponsorship of the Female Health Company and Mayer Laboratories, Inc., is offering the Female Condom(R) and Kimono & MAXX latex male condoms at no cost during National Condom Week. Dr. John E. Anderson of the Centers for Dis
ST. PAUL, Minn., Feb. 13 /PRNewswire/ -- Writing in the Feb. 15 edition of The Annals of Internal Medicine (ASIM), a prestigious national physician peer-review medical journal, Dr. Keith Henry, medical director of the HIV Clinic at Regions Hospital, calls for an overhaul of the current approaches toward treating and fu
OAKLAND, Calif., Feb. 10 /PRNewswire/ -- NBA Basketball Great EARVIN MAGIC JOHNSON has joined the AIDS HEALTHCARE FOUNDATION (AHF), the largest direct provider of HIV/AIDS care in the U.S., in unveiling THRIVE Magazine, a new national magazine targeting minorities living with and impacted by HIV and AIDS. THRIVE Magazi
CARLSBAD, Calif., Feb. 10 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received two patents from the United States Patent and Trademark Office covering methods and compositions relating to immune-based therapies for the prevention and treatment of retroviral diseases, such
WILMINGTON, Del., Feb. 10 /PRNewswire/ -- DuPont Pharmaceuticals today announced that its anti-HIV medication Sustiva (TM) ( efavirenz ) is the first to receive traditional (full) approval based on a new U.S. Food and Drug Administration ( FDA ) standard that measu
SAN FRANCISCO, Feb. 9 /PRNewswire/ -- Aggressive AIDS Prevention has developed a series of public service web banner ads for National Condom Week illustrating the cause and effect relationship of non-consistent condom use. The ads challenging messages address the issues that HIV/AIDS is still a preventable terminal dis
ANCHORAGE, Alaska, Feb. 8 /PRNewswire/ -- Chuck King, 39, a former pulmonary trauma surgeon now living with AIDS, has just placed first in the Willow/Su Valley 300-mile Sled Dog Race, the first of two qualifying races for the prestigious Iditarod Sled Dog Race, which begins on March 4. For an amateur to just finish the
NEW YORK, Feb. 8 /PRNewswire/ -- The Catholic Medical Mission Board (CMMB) and the Southern African Catholic Bishops Conference (SACBC) will join pharmaceutical leader Bristol-Myers Squibb (BMS) (NYSE: BMY) in its multi-million dollar public-private partnership to combat HIV/AIDS in five countries of sub-Saharan Africa
PLEASANTVILLE, N.Y., Feb. 8 /PRNewswire/ -- Do needle-exchange programs really save lives? Prevent disease? Or do they only create more casualties in the nation s war on drugs? To find out, Reader s Digest Senior Editor Dan Levine watched one of America s free-needle exchanges in action. And sadly, he saw how drug abus
NEW HAVEN, Conn., Feb. 8 /PRNewswire/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION) and Achillion Pharmaceuticals, Inc. today announced that they have signed a licensing agreement for Vion s novel antiviral technology, nucleoside analog B(beta)-L-Fd4C, for the potential treatment of HBV and HIV. Achillion, a privately h
PRNewswire, Feb 7: amfAR s May 18 Cinema Against AIDS 2000 benefit at the Cannes International Film Festival promises to be the most exciting ever, as the spectacular annual Victoria s Secret fashion show and webcast move to the south of France to join Miramax Films in the star-studded fundraiser. The highlight of
LOS ANGELES, Feb. 7 /PRNewswire/ -- Click2Asia, the online community uniting Asians globally, will utilize the broad reach of the Internet to raise money for the fight against AIDS by hosting the first live Web-A-Thon to benefit the Asian Pacific AIDS Intervention Team (APAIT). The event will be Web-casted for 24 strai
TORONTO, Feb. 7 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGIN) announced that the recently released U.S. Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV- Infected Adults and Adolescents, further validates the potential utility of genotypic testing in the
SAN FRANCISCO, Feb. 4 /PRNewswire/ -- A new retrospective analysis showed that a greater proportion of HIV infected patients treated early with a combination including Crixivan (R) ( indinavir sulfate), zidovudine(1) (ZDV) and lamivudine(2) (
RESEARCH TRIANGLE PARK, N.C., Feb. 4 /PRNewswire/ -- Eleven programs across the country designed to address the healthcare needs of incarcerated individuals have received a total of $175,000 in grant support from Glaxo Wellcome . The grants will fund programs that are designed to educate inmates about the value of know
WILMINGTON, N.C. and LA JOLLA, Calif., Feb. 4 /PRNewswire/ -- PPD Discovery, a wholly owned subsidiary of PPD, Inc. (Nasdaq: PPDI), and Agouron Pharmaceuticals, Inc. today announced an exclusive four-year alliance to identify new targets for therapeutic agents against Human Immunodeficiency Virus (HIV). The collabo
WEST BRIDGEWATER, Mass., Feb. 3 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII) announced today the signing of a Materials Transfer Agreement (MTA) with the National Institutes of Health (NIH), the Department of Defense (DOD), and the European Network for Virological Assessment of New HIV Therapies (ENVA) to tran
SAN FRANCISCO, Feb. 3 /PRNewswire/ -- Two late breaker abstracts and nine other presentations employing ViroLogic s PhenoSense HIV assay were presented this week at the 7th Conference on Retroviruses and Opportunistic Infections, the meeting widely regarded as the most scientifically prestigious conference on HIV. The
ABBOTT PARK, Ill., Feb. 3 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today data from three studies of Norvir (R) (ritonavir), in combination with several other protease inhibitors (PIs), that show promise against the HIV virus.
SAN FRANCISCO, Feb. 3 /PRNewswire/ -- Results demonstrating the significant potency of VIRAMUNE(R) ( nevirapine , NVP) were presented today at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco/USA. Findings show VIRAMUNE added to a combination of
SAN FRANCISCO, Feb. 2 /PRNewswire/ -- U.S. Department of Veterans Affairs (VA) researchers in San Diego and Pittsburgh have found that two new drugs they developed can inhibit HIV strains highly resistant to drugs commonly used to fight the AIDS virus. The findings, reported at the 7th Conference on Retroviruses and Op
SAN FRANCISCO, Feb. 2 /PRNewswire/ -- Immune system and resistance data from a study comparing a triple nucleoside regimen of Ziagen (R) ( abacavir sulfate) and Combivir (R) (lamivudine/zidovudine) to a regimen of indinavir sulfate (Me
SAN FRANCISCO, Feb. 2 /PRNewswire/ -- Two new studies about the resistance profile of Agenerase (TM) ( amprenavir ) were presented at a major scientific meeting in San Francisco today. The first study evaluated the cross resistance to Agenerase in protease inhibitor (PI) treated patients and the
SAN FRANCISCO, Feb. 2 /PRNewswire/ -- United Biomedical , Inc. (UBI) of Hauppauge, NY, has developed a synthetic peptide vaccine p2249f. The peptide vaccine evokes potent antibodies effective against a broad range of HIV primary isolates. These are the diverse viruses in worldwide circulation that are responsible for A
ABBOTT PARK, Ill., Feb. 2, /PRNewswire/ -- Data presented at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco suggest that Abbott Laboratories advanced-generation protease inhibitor (PI) ABT-378/ ritonavir may provide viral suppression in HIV-positive patients who have previously failed
SAN FRANCISCO, Feb. 2 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today announced results from the Pediatric AIDS Clinical Trials Group (PACTG) study 353 of the HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) in combination therapy specifically in pregnant women, and the impact of gestational and postpartum
SAN FRANCISCO, Feb. 2 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported that among HIV-infected patients who failed exclusive treatment with nucleoside reverse transcriptase inhibitors (NRTIs), those patients switching to a triple class regimen containing the HIV protease inhibitor (PI) VIRACEPT(R) (nelfinav
SAN FRANCISCO, Feb. 2 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) presented new data on the Company s HIV programs today at the 7th Conference on Retroviruses and Opportunistic Infections. The findings were discussed in presentations, which were made on three different antibody and vaccine programs c
DURHAM, N.C., Feb. 2 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced that it will present the initial results of a Phase I/II 14-day monotherapy study today at a scientific conference. The study was designed to assess the anti-HIV activity, tolerability and pharmacokinetics of DAPD in HIV-infect
LOS ANGELES, Feb. 1 /PRNewswire/ -- The following is being issued by Craig E. Thompson, Executive Director of AIDS Project Los Angeles: In AIDS Project Los Angeles prevention efforts, oral sex has always been considered a risky behavior. Studies over the years have told us that oral sex is low risk, but low risk does n
SAN FRANCISCO, Feb. 1 /PRNewswire/ -- Preliminary 48 week data from an ongoing study of patients with undetectable levels of HIV who switched from a protease inhibitor-containing regimen to a regimen of Ziagen (R) ( abacavir sulfate)+ Comb
ABBOTT PARK, Ill., Feb. 1 /PRNewswire/ -- Abbott Laboratories novel, advanced-generation protease inhibitor, ABT-378/ ritonavir , continues to show antiretroviral activity at 72 weeks of therapy, according to data from an ongoing Phase II study presented at the 7th Conference on Retroviruses and Opportunistic Infection
SAN FRANCISCO, Feb. 1 /PRNewswire/ -- Sarawak MediChem Pharmaceuticals, Inc., at the 7th Conference on Retroviruses and Opportunistic Infections, is releasing results today of clinical tests of its rainforest anti-HIV drug, (+)-calanolide A, that suggest the new plant-based compound may prove to be a potent weapon in t
DURHAM, N.C., Feb. 1 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced that researchers from the Agence Nationale de Recherche sur le SIDA (ANRS) in France will present preliminary data today from a pilot study. The data demonstrate that a once-a-day HAART (highly active antiretroviral therapy) re
SAN FRANCISCO, Jan. 31 /PRNewswire/ -- A new study released today suggests that phenotypic testing improves HIV treatment choices by physicians and significantly improves the viral suppression seen with antiviral medications. The study examined the role of using HIV phenotypes for medication susceptibility versus just
DETROIT, Jan. 31 /PRNewswire/ -- Ned NcGrath, Director of Communications for the Catholic Archdiocese of Detroit, issued this statement in response to the Kansas City Star news series -- AIDS in the Priesthood: A Church s Challenge : The reaction from Catholic leaders in Kansas City-St. Joseph is on-point. At best, The
SAN FRANCISCO, Jan. 31 /PRNewswire/ -- Interim results of a study (CNA30017) examining the effects of changing HIV patients therapies from a protease inhibitor containing regimen (standard-of-care regimen) to a triple nucleoside reverse transcriptase (NRTI) regimen that included Ziagen (R) (
PRINCETON, N.J., Jan. 31 /PRNewswire/ -- Back-to-back research conferences featuring the latest pharmaceutical industry research advances in antibiotic and antiviral discovery and clinical development will take place at the Princeton Hyatt Regency Hotel, announces Strategic Research Institute. The 5th Antibacterial Dru
RICHMOND, Calif., Jan. 31 /PRNewswire/ -- Neurobiological Technologies, Inc. (OTC Bulletin Board: NTII) today announced that patient enrollment has been completed in a double-blind, placebo-controlled Phase II human clinical trial of Memantine for AIDS-related dementia . The trial is funded by the National Institute of
RARITAN, N.J., Jan. 31 /PRNewswire/ -- SPORANOX(R) (itraconazole) Injection is now available for the treatment of potentially life-threatening fungal infections, including blastomycosis, histoplasmosis and aspergillosis in patients who are intolerant of or refractory to amphotericin B, a first-line therapy. These deadl
SAN FRANCISCO, Calif., Jan. 30 /PRNewswire/ -- The following release was issued today by Glaxo Wellcome : New studies to determine the interaction of Agenerase (TM) ( amprenavir )+ ritonavir
SAN FRANCISCO, Jan. 30 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported that the investigational drug capravirine (formerly AG1549), showed antiretroviral activity and was well-tolerated in a short course monotherapy trial of HIV-infected patients. In a second trial to examine pharmacokinetics, capravirine
SAN FRANCISCO, Jan. 30 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported that, in a twelve-month followup analysis of patients in three HIV protease inhibitor trials, antiretroviral combination therapy containing protease inhibitors plus reverse transcriptase inhibitors (RTIs) did not show an increase in
INGELHEIM, Germany and PEAPACK, N.J., Jan. 28 /PRNewswire/ -- Boehringer Ingelheim GmbH International and Pharmacia & Upjohn (NYSE: PNU) announced today that Boehringer Ingelheim has acquired worldwide rights for Pharmacia & Upjohn s investigational protease inhibitor, tipranavir.
DAVOS, Switzerland , Jan. 27 /PRNewswire/ -- Seth Berkley, M.D., president of the International AIDS Vaccine Initiative, issued the following statement at the World Economic Forum in response to U.S. President Bill Clinton s Millennium Vaccine Initiative: President Clinton s initiative is a giant step forward in the gl
WASHINGTON, Jan. 26 -- A French Countess who pledged in September 1999 to pressure the 500 richest people in the world to set up a $40 billion endowment for the AIDS orphans of this decade takes her case to the World Bank here on Monday. Albina du Boisrouvray -- granddaughter of Bolivian tin baron Simon Patino, acclaim
NEEDHAM, Mass., Jan. 26 /PRNewswire/ -- AVANT Immunotherapetics, Inc. (Nasdaq: AVAN) announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) for the use of Therapore(TM)-P24 in the development of a vaccine candidate agains
GABERONE, BOTSWANA, Jan. 25 /PRNewswire/ -- Bristol-Myers Squibb Foundation Inc. today announced that Secure The Future Community Outreach and Education grants have been made to support community projects run by the Botswana Christian Aids Intervention Program (BOCAIP) and the Reetsanang Association of Community Dram
CARLSBAD, Calif., Jan. 25 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced that treatment of patients has begun in a trial designed to examine the effects of its investigational immune-based therapy REMUNE(TM) in combination with Highly Active Antiretroviral Therapy (HAART) when administer
PRINCETON, N.J., Jan. 24 /PRNewswire/ -- Back-to-back conferences/expositions featuring the latest pharmaceutical industry research advances in antibiotic and antiviral discovery and clinical development will take place at the Princeton Hyatt Regency Hotel, announces Strategic Research Institute. The 5th International
WEST HOLLYWOOD, Calif., Jan. 24 /PRNewswire/ -- At a press conference held today at West Hollywood City Hall, several civic, community and religious leaders strongly denounced a recent and ugly act of anti-Semitic and homophobic hate speech in West Hollywood fueled by the recent controversy over condom distribution in
SAN MATEO, Calif., Jan. 27 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the start of a U.S. Phase 2 hepatitis B study using ZADAXIN, the Company s host immune system enhancer (h-ISE), in combination with lamivudine, an FDA-approved nucleoside analogue. The study, conducted at Loyola Universit
SOUTH SAN FRANCISCO, Calif., Jan. 21 /PRNewswire/ -- Loss of HIV suppression during potent antiretroviral therapy may be connected to a number of factors, including suboptimal drug potency, according to a study published January 12 in the Journal of the American Medical Association . The study, led by Dr. Diane Ha
HARRISBURG, Pa., Jan. 19 /PRNewswire/ -- On behalf of Pennsylvania Gov. Tom Ridge, Health Secretary Robert S. Zimmerman today announced that the state has begun airing a powerful, new television commercial to encourage women of child-bearing age to get an HIV test. Early detection and treatment of HIV and AIDS in pregn
PITTSBURGH, Jan. 18 /PRNewswire/ -- The University of Pittsburgh has been awarded a major AIDS research grant to become part of the Adult AIDS Clinical Trials Group (AACTG), the world s largest clinical trials network, which is sponsored by the National Institutes of Health s National Institute of Allergy and Infectiou
VICTORIA, British Columbia and CAMBRIDGE, Mass., Jan. 17 /PRNewswire/ -- StressGen Biotechnologies Corp. (Toronto: SSB) announced today the publication of preclinical experiments demonstrating that the Company s stress proteins created a specific immune response in both immune compromised and normal mice using CD8+ T c
WASHINGTON, Jan. 14 /PRNewswire/ -- The National Minority AIDS Council urgently calls for an increase in resources targeted to support HIV prevention and care projects for men of color who have sex with men and for these projects to be provided by gay men of color for gay men of color. This call comes in response to th
LOS ANGELES, Jan. 13 /PRNewswire/ -- The report, from the January 14th issue of the Center for Disease Control s Morbidity and Mortality Weekly Report, finds that HIV/AIDS cases among gay and bisexual men of color now exceed cases among white gay and bisexual men. AIDS cases among gay and bisexual men of color now repr
TARRYTOWN, N.Y., Jan. 11 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced an important scientific discovery that may significantly help in the development of an effective vaccine against HIV, the virus that causes AIDS. The finding is described in the Journal of Virology (vol. 74, no. 2) a
KAMPALA, Uganda , Jan. 10 /PRNewswire/ -- The following is a statement by Kate S. Carr, Chief Executive Officer of the Elizabeth Glaser Pediatric Aids Foundation: We applaud Vice President Gore s call today before the United Nations Security Council to substantially increase resources to fight HIV and AIDS in the devel
NEW YORK, Jan. 10 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI), a collaborating center of the Joint United Nations Programme on AIDS ( UNAIDS ), hailed the Security Council for devoting the first session it has ever held on a health issue to the African AIDS epidemic. IAVI also called upon world lea
NEW YORK, Jan. 9 /PRNewswire/ -- A 55 percent majority of U.S. adults say they have personally seen little or nothing about the AIDS crisis in sub-Saharan Africa, according to a new Newsweek poll. And only 18 percent of Americans correctly estimate the total number of dead or dying of AIDS/HIV in the region so far as o
LOS ANGELES, Jan. 6 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announced today that it received $1 million from Ty Inc. from the first-ever global beanie baby vote. Ty Inc. more than doubled its pledge to triple funds raised by the vote. Our heartfelt thanks to all our friends at Ty Inc. and beanie
ST. PAUL, Minn., Jan. 6 /PRNewswire/ -- Hughes Institute scientists announce the development of a new agent shown to have potent activity against multi-drug resistant strains of HIV. The results of this research are reported in the December issue of Bioorganic and Medicinal Chemistry Letters. A major obstacle in the tr
MADISON, N.J., Jan. 5 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it submitted a Biologics License Application (BLA) on Dec. 23, 1999 to the U.S. Food and Drug Administration ( FDA ) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for the treatm
SUNNYVALE, Calif., Jan. 5 /PRNewswire/ -- According to a new study published in today s issue of Virology, genes involved in T-cell signaling, protein trafficking and transcriptional regulation were among the genes that displayed functional changes within three days of exposure to the HIV virus. Conducted by researcher
AIDS Healthcare Foundation to File Over 4,500 Ballot Measure Signatures For Mandatory Availability of Condoms in West Hollywood Goal: Allow City s Voters to Decide Critical Public Health Issue What: Presentation & Filing with City Clerk of Over 4,500 Signatures for Mandatory Condom Ballot Measure (2,310 needed to Q
ARLINGTON, Texas, Jan. 4 /PRNewswire/ -- New legislation passed today by the state of New Jersey recognizes the importance of reducing accidental needlesticks and the role such injuries play in transmitting HIV, hepatitis, and other life-threatening, blood-borne diseases. With the signing of this bill, the New Jersey l
This information is designed to support, not replace, the relationship that exists between you and your doctor.